Print

Search Results: (237 results)

Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor

Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor

The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.

ShareForCures: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

https://www.facingourrisk.org/research-clinical-trials/study/295/shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.

Comparing Screening Methods for Detection of Early-Stage Gastric Cancer in People with a CHD1 Genetic Mutation

https://www.facingourrisk.org/research-clinical-trials/study/293/comparing-screening-methods-for-detection-of-early-stage-gastric-cancer-in-people-with-a-chd1-genetic-mutation

Prevention
Gastric cancer screening study for people with a CHD1 inherited mutation

This study will compare a new technique of screening for a type of inherited gastric cancer known as diffuse hereditary gastric cancer (DHGC) to see if it can identify cancer better than the current recommended screening. 

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u

Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

https://www.facingourrisk.org/research-clinical-trials/study/149/promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations;screening approximately 5,000 participants with a prostate cancer diagnosis.

The PROMISE team is studying how these mutations affect patient outcomes.

A clinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer: VERITAC-2

https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies

Treatment
A clinical trial for ER-positive, HER2-negative advanced breast cancer

Researchers at Pfizer and Arvinas are conducting the VERITAC-2 cinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer that has profressed after previous treatment. This clinical trial is specifically for people who have already been treated with CDK4/6 inhibitor* therapy in combination with hormone therapy for their locoregional recurrent/metastatic disease.

* CDK4/6 inhibitors include medications called palbociclib (IBRANCE®), ribociclib (KISQALI®), and abemaciclib (Verzenio®).

PreCharge: Digital Program for People Affected by Hereditary Cancer

https://www.facingourrisk.org/research-clinical-trials/study/292/precharge-digital-program-for-people-with-hereditary-cancer-syndromes

Quality of Life
Study to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being

PreCharge is an IRB approved, nationwide study funded by the National Cancer Institute. The purpose of this study is to test a digital program designed to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being.

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

Interviews with Young Women with a BRCA Mutation About Their Breast Cancer Risk Management Experiences

https://www.facingourrisk.org/research-clinical-trials/study/297/interviews-with-young-women-with-a-brca-mutation-about-their-breast-cancer-risk-management-experiences

Surveys, Registries, Interviews
Young women with a BRCA mutation

This research study focuses on young women’s emotional experiences when considering or engaging in strategies to manage increased breast cancer risk.

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/294/high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation

Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

This study will examine how well an increased dose of testosterone treatment works for people with metastatic castration-resistant prostate cancer (mCRPC) with an ATM, CDK12, or CHEK2 genetic mutation. Participants will continue to receive the medication as long as their cancer doesn’t get worse and they do not experience severe side effects.

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study

Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

FORCE Survey for People at Increased Risk for Breast or Gynecologic Cancer Due to an Inherited Mutation

https://www.facingourrisk.org/research-clinical-trials/study/287/survey-for-people-at-increased-risk-for-breast-or-gynecologic-cancer-due-to-an-inherited-mutation

Surveys, Registries, Interviews
Survey for people at high risk for breast and gynecologic cancer due to an inherited mutation

FORCE is conducting a short survey to better understand the unmet needs of people who are at high risk for breast or gynecologic cancer due to an inherited mutation. You can take the survey here. 

Men at High Genetic Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/278/cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome

Prevention
Prevention study for people with Lynch syndrome

This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/286/swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Prevention
Screening study for people with a mutation linked to prostate cancer risk

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation

Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation.

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation

https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment

Treatment
Study for metastatic colorectal cancer that has not yet been treated

This study is being done to learn about the effects of using three study medicines together as treatment for metastatic colorectal cancer that has been previously untreated.

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will depend on when they join the study. 

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/285/

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

The usual care after a person with stage 3 colon cancer has had surgery and chemotherapy is to begin active surveillance. This is a time when no additional treatment is given, but instead patients have frequent imaging scans to see if their cancer has come back.

This study is looking at whether a blood test known as circulating tumor DNA (ctDNA) can find signs of remaining cancer or recurrence after treatment earlier than standard active surveillance. People in the study who have evidence of cancer in their ctDNA test may receive additional treatment based on their test results. The goal of this study is to learn if using ctDNA and additional treatment improves outcomes in people after treatment for stage 3 colon cancer. Currently, testing with ctDNA is not part of standard of care to determine if colon cancer treatment was successful or if there is a recurrence. 

Lynch Syndrome Vaccine Study

https://www.facingourrisk.org/research-clinical-trials/study/273/testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome

Prevention
Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

Exploring How People of Caribbean Descent Share Information About Their Genetic Mutations with Family Members

https://www.facingourrisk.org/research-clinical-trials/study/275/exploring-how-people-of-caribbean-descent-share-information-about-their-genetic-mutations-with-their-family-members

Surveys, Registries, Interviews
Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.

We're looking into how families share information among Caribbean individuals who have a genetic mutation linked to an increased risk of cancer. The goal is to understand the experiences of Caribbean people dealing with a higher chance of developing cancer. This study will help us figure out how genetic counselors can better support Caribbean patients and their family members in handling this genetic information. If you're interested, you can participate by filling out a survey. If you're eligible, we might reach out to you for a 45-60 minute interview. 

Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

This study will compare a combination of drugs for people who have HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting.

Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/239/preferences-survey-for-women-with-an-inherited-brca-mutation-and-without-a-cancer-diagnosis


Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.

We hope to understand women’s preferences about the benefits and effects of cancer-preventing surgeries. In this survey of women ages 25-50 with an inherited BRCA1 or BRCA2 mutation and no personal history of cancer, we present scenarios and ask participants to make hypothetical choices. Your responses will help us to design educational tools for people who are at high risk of breast and ovarian cancer who face personal decisions about cancer prevention.

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. 

Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer

Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients, CORAL Study

https://www.facingourrisk.org/research-clinical-trials/study/256/early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome

Prevention
People with Lynch Syndrome at risk for colon cancer

This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome.

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

The WISDOM Study: Women Informed to Screen Depending on Measures of Risk

https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study

Prevention
Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website. 

LIVING WELL: A Web-Based Program to Improve Quality of Life in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/270/living-well-a-web-based-program-to-improve-quality-of-life-in-ovarian-cancer-survivors

Quality of Life
A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors.

A free research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors. 

MRI Screening in Men at High Risk of Developing Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer

Prevention
Screening using MRI for men at risk of developing prostate cancer

This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.

Study for Women at Increased Risk of Developing Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/257/study-for-women-at-increased-risk-of-developing-breast-cancer

Prevention
This study will create a system to assess an individual’s risk of breast cancer

This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.

My Best GI Eating Study

https://www.facingourrisk.org/research-clinical-trials/study/258/my-best-gi-eating-study

Prevention
Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer

This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss. 

 

Intimacy and Self-Esteem Among Sexual and Gender Minority Cancer Survivors (RISE-SGM)

https://www.facingourrisk.org/research-clinical-trials/study/265/an-interview-about-intimacy-and-self-esteem-for-sexual-and-gender-minority-cancer-survivors

Surveys, Registries, Interviews
A one-time interview study to explore experiences with sexual functioning, sexual relationships, sexual self-concept, and self-esteem of 18-39-year-old sexual and/or gender minority cancer survivors

Relationships, Intimacy, and Self-Esteem among Sexual and Gender Minority Cancer Survivors (RISE) is a research study that focuses on the experiences of 18-39-year-old sexual and/or gender minority cancer survivors. Participants will be asked to complete an interview on relationships, self-esteem, and intimacy.

Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )

https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families

The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation.

Registry to Promote Health Equity for People of African Ancestry with Breast or Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/277/registry-to-promote-health-equity-for-people-of-african-ancestry-with-breast-or-prostate-cancer

Surveys, Registries, Interviews
This is a registry for people of African ancestry who have breast or prostate cancer

The purpose of this research is to study and understand the genetic and molecular causes of breast and prostate cancer in people with African ancestry.

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women (TUBA/WISP II)

https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Prevention
Prevention study for women at high risk for ovarian cancer

This study is looking at whether removal of the fallopian tubes (salpingectomy) followed by removal of the ovaries (oophorectomy) at a later date closer to the time of natural menopause may reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes at the same time (salpingo-oophorectomy) among women with an inherited BRCA1, BRCA2, BRIP1, RAD51C or RAD51D mutation. Removing the fallopian tubes only first and the ovaries at a later time closer to natural menopause may lessen menopausal symptoms while still lowering the risk for ovarian cancer.

 

Coaching for Family Caregivers of People with Advanced Cancer from Rural and Minority Communities

https://www.facingourrisk.org/research-clinical-trials/study/272/quality-of-life-study-for-caregivers-involving-in-person-or-telephone-coaching-sessions

Quality of Life
Quality of life study for caregivers involving in-person or telephone coaching sessions

This study is for families with patients that have newly-diagnosed advanced cancer. African American family caregivers and family caregivers living in rural communities will be eligible.

Survey For Individuals With A Hereditary Cancer Genetic Testing Result That Was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/261/survey-for-individuals-with-a-hereditary-cancer-genetic-testing-result-that-was-later-reclassified


Survey for people whose genetic test results were reclassified

Researchers are conducting an online survey to look into the personal experiences of people who received reclassfied genetic testing results for hereditary cancer gene mutations. 

Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis

https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis

Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery

This study is looking at whether obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in people with familial adenomatous polyposis (FAP). OCA is a drug similar to a bile acid the body's liver makes. Researchers believe OCA may help keeping cancer from developing. OCA is already FDA approved to treat a type of liver disease. There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation

Prevention
People with a BRCA1 or BRCA2 mutation

This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers. 

Survey about Motivations and Barriers to Talking with Family Members about Inherited Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/280/survey-about-goals-of-inherited-cancer-risk-disclosure-in-families-with-an-inherited-gene-mutation

Surveys, Registries, Interviews
Survey for people with an inherited gene mutation

This study aims to understand the different goals and motivations individuals with an inherited gene mutation have when talking about their genetic cancer risk with family members in a conversation.

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer

Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 

Cancer Screening for People With Intellectual Disability: Exploring Parent and Caregiver Perspectives

https://www.facingourrisk.org/research-clinical-trials/study/268/parent-and-caregiver-perspectives-on-cancer-screening-for-people-with-intellectual-disabilities


Survey for parents and caregivers to share perspectives on cancer screening for people with intellectual disabilities

Our goal is to understand the experiences of people with intellectual disability in regard to screening for cancer, for example colonoscopies for colon cancer and mammograms for breast cancer. For people not being screened, we hope to learn about any barriers faced.

A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome

Prevention
Prevention study for people with Lynch syndrome

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

What Factors Influence Survivors’ Guilt in Individuals Who Tested Negative for a Known Hereditary Cancer Syndrome?

https://www.facingourrisk.org/research-clinical-trials/study/264/survey-for-people-who-received-a-negative-genetic-test-result-for-a-known-mutation-in-the-family


People who received a negative genetic test result

This study is to understand the experiences of people who have received a negative genetic test result for a known familial hereditary cancer mutation (i.e., a “true negative” result) and determine what factors influence the presence of survivors’ guilt in these individuals.

Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/254/comparing-the-safety-and-effectiveness-of-secondary-treatments-in-patients-with-her2-negative-early-breast-cancer


Treatment study for people with early-stage breast cancer

This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer. 

Kindred Study

https://www.facingourrisk.org/research-clinical-trials/study/255/kindred

Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation

We are talking with African American adults about cancer genetic testing, including those that have received a positive cancer genetic testing result and people with a family member who received testing. 

Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced cancers

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Self -Perception and Intimacy After the Cancer Experience (SPICE)

https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health

Survey for cancer survivors ages 18-39 years old about sexual self-concept, sexual health knowledge, relationships and body image.

Metastatic Castration Resistant Prostate Cancer Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/240/metastatic-castration-resistant-prostate-cancer-clinical-trial

Treatment
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.

Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC).  This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment.  Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.

Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/246/comparing-the-drugs-opdualag-and-stivarga-as-late-stage-treatment-for-individuals-with-metastatic-colorectal-cancer


treatment study for people with metastatic colorectal cancer

This study is being done to look at how well a combination of three drugs works for the treatment of metastatic colorectal cancer in patients who have had their cancer come back or get worse after treatment. The study is open to people who have had at least one, but no more than four courses of treatment in the metastatic setting. 

Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/242/investigating-the-use-of-self-acupressure-for-fatigue-in-ovarian-cancer-survivors

Quality of Life
University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.

Study using acupressure for people experiencing fatigue after ovarian cancer treatment.

Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/244/treatment-for-advanced-or-recurrent-endometrial-cancer


Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if  pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).

 

Survey for Women at High Risk for Breast Cancer on Knowledge and Perspectives about Breast Cancer Risk Factors and Screening

https://www.facingourrisk.org/research-clinical-trials/study/238/survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening

Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.

Researchers at the Mayo Clinic and McGill University are partnering with FORCE on a survey of women who have inherited mutations in BRCA1, BRCA2 or other genes (including PALB2, ATM, CHEK2, and others) related to increased breast cancer risk. We are interested in the effects of testing positive for an inherited mutation on decisions about the timing of pregnancy, breastfeeding, breast cancer screening and risk-reducing surgery. 

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

https://www.facingourrisk.org/research-clinical-trials/study/175/niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects

Treatment
High-risk localized prostate cancer

This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.

.

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer

Treatment
Treatment study for people with endometrial cancer that has returned

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.

Opening the Conversation

https://www.facingourrisk.org/research-clinical-trials/study/228/opening-the-conversation

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners

This is a clinical trial sponsored by the American Cancer Society, where we will be testing the helpfulness of two programs designed to teach breast and gynecological cancer survivors and their partners to communicate and cope with physical, emotional, and relationship challenges after cancer. The programs are conducted entirely via videoconference (Zoom), so neither you nor your partner would have to travel anywhere to participate.

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Treatment
Treatment study for people with advanced solid tumors

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer

Treatment
Stage 4 colorectal cancer

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.

Women's Sexuality After Gynecological Cancer Treatments

https://www.facingourrisk.org/research-clinical-trials/study/243/womens-sexuality-after-gynecological-cancer-treatments


Virtual or in-person interview to share personal experiences of sexuality after gynecological cancer treatment(s).

Explore women's lived experiences of sexuality after gynecological cancer treatment(s).

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/226/survey-for-people-diagnosed-with-breast-cancer-to-provide-feedback-on-a-new-type-of-clinical-trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer

Stanford researchers invite people diagnosed with stage 0 to stage 3 breast cancer to take this 15 minute survey to share your thoughts about the advantages and disadvantages of participating in a new type of clinical trial called “a window opportunity” trial. will use this information to help design future clinical trials.

Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5

Prevention
Screening study for people at high risk for pancreatic cancer

CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

 

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

https://www.facingourrisk.org/research-clinical-trials/study/156/combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri

Treatment
Recurrent ovarian cancer

This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/219/effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer

Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer

The purpose of this study is to test whether acupuncture can improve thinking and memory difficulties in breast cancer survivors. Researchers will look at whether  acupuncture improves memory, thinking and sleep in breast cancer survivors. This study will also look at the link between lack of sleep and thinking difficulties.

Restoring Sensation after DIEP Flap Reconstruction

https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction

Prevention
Study for people undergoing DIEP flap reconstruction

The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap). 

 

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation

Treatment

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance.

TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration

https://www.facingourrisk.org/research-clinical-trials/study/153/talapro-3-a-clinical-trial-in-men-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-dna-damage-repair-ddr-gene-alteration

Treatment
Metastatic castration-sensitive prostate cancer

The TALAPRO-3 trial is assessing whether the study drug, talazoparib, is effective and safe when given in combination with enzalutamide as a treatment option for men with metastatic castration-sensitive prostate cancer and a DDR gene alteration.

For more information about the study, visit www.Talapro3ClinicalTrial.com

Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/225/effects-of-occupational-therapy-telehealth-intervention-on-cancer-related-cognitive-impairment-in-breast-cancer-survivors

Quality of Life
Telehealth study for breast cancer survivors with memory issues

The purpose of this study is to look at the effects and ease of use of occupational therapy delivered by telehealth on activity performance, memory and quality of life in breast cancer survivors. Participants will complete all sessions from home via Zoom videoconferencing. This is a 2-arm randomized control trial, which means that each participant will be randomly assigned to one of two groups. Participants will complete the same number of sessions regardless of which group they are assigned to.

Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/249/study-of-two-drugs-in-er-andor-pr-cancers-with-pi3k-andor-pten-tumor-or-inherited-mutations


People with advanced breast or endometrial or ovarian cancer

This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers.  People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors

Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer

Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.

Paid Research Interview Opportunity: Stage III or IV Ovarian Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/237/paid-research-interview-opportunity-patients-receiving-neoadjuvant-or-first-line-treatment-for-ovarian-cancer


Interview for people with stage III or IV ovarian cancer

Modus Outcomes is seeking patients with stage III or IV ovarian cancer to participate in online interviews. We will ask you questions about your symptoms and how ovarian cancer impacts your life. Then, we will ask for feedback on questionnaires used in ovarian cancer studies.

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

https://www.facingourrisk.org/research-clinical-trials/study/223/factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer

Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer

This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.

We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.

Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers

https://www.facingourrisk.org/research-clinical-trials/study/232/testing-a-targeted-therapy-in-combination-with-chemotherapy-for-advanced-solid-tumors


Treatment study for people with advanced cancers

This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Prevention
People at high risk for prostate cancer due to an inherited mutation

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

Perceptions of an Online Platform to Facilitate Sharing of Family Health History

https://www.facingourrisk.org/research-clinical-trials/study/241/perceptions-of-an-online-platform-to-facilitate-sharing-of-family-health-history


Online survey for people with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53 inherited mutation or Lynch syndrome.

Online survey for people with a family history of hereditary breast and ovarian cancer and Lynch syndrome about online health history-sharing.

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

https://www.facingourrisk.org/research-clinical-trials/study/183/parp-inhibitor-niraparib-in-patients-with-inherited-or-tumor-palb2-mutations-in-advanced-solid-tumors-pavo


Any advanced or metastatic solid tumor except ovarian or prostate

PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Opening the Conversation Study

https://www.facingourrisk.org/research-clinical-trials/study/214/opening-the-conversation-study

Quality of Life
Videoconference sessions that address cancer related concerns for couples

This study will adapt and evaluate an intervention designed to help young couples cope with and communicate about cancer-related reproductive and sexual health concerns.

 

Project MTFM: Medical Tattooing Following Mastectomy

https://www.facingourrisk.org/research-clinical-trials/study/233/project-mtfm-medical-tattooing-following-mastectomy


Survey for breast cancer survivors following mastectomy

This study aims to better understand how breast cancer surgery can impact mental health and wellness. We will also explore how breast cancer survivors view breast cancer surgery and medical tattooing following. Participation includes an optional information session and consultation with a medical tattoo artist. 

Study of Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/220/physical-activity-at-home-for-relief-from-neuropathy-caused-by-taxanes-in-people-with-breast-cancer

Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy

Chemotherapy-induced peripheral neuropathy (CIPN) symptoms include numbness combined with tingling sensations, persistent shooting, stabbing, or burning pain even in the absence of an obvious cause, lower extremity muscle weakness, and impaired balance. Resistance exercise has shown promising results; however, the effect of exercise on CIPN remains understudied. This study will look at the effects of gain and balance training and resistance exercise (using bands) on gait, balance, and lower extremity muscle strength after a 16-week home-based exercise program compared to educational materials without an exercise program.

 

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

https://www.facingourrisk.org/research-clinical-trials/study/210/treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.

Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

A New Risk Measurement Tool for Those at High Risk for Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/236/a-new-risk-measurement-tool-for-those-at-high-risk-for-ovarian-cancer


This study is using a new type of genetic test to measure ovarian cancer risk

This study is using a new type of genetic test to measure ovarian cancer risk in women who have inherited genetic mutations that increase their risk for ovarian cancer or women who have an ovarian cyst or other non-cancerous masses (adnexal mass). NOTE: This study is no longer enrolling patients. 

Exploring the Psychosocial Implications of Individuals with a Genetic Test Result that was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/229/exploring-the-psychosocial-implications-of-individuals-with-a-genetic-test-result-that-was-later-reclassified

Prevention
Interview for people who's genetic test results were reclassified

Researchers at Bay Path University are conducting virtual/phone interviews with individuals who have received a reclassified genetic test result to cancer related genes. This study will help researchers learn the psychosocial implications and experiences of those who have received a reclassified genetic test result when undergoing hereditary cancer gene testing, (for example, your original genetic test results showed a variant of uncertain significance that was later found to be harmful or harmless). 

Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care

https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care

Prevention
Latinas with a high risk of breast cancer

This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.

Upright MRI for Prostate Cancer Screening

https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening

Prevention
Screening for prostate cancer using upright MRI

This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.

Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/218/bazedoxifene-plus-conjugated-estrogens-for-hot-flashes-in-women-at-high-risk-for-breast-cancer

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes

Bazedoxifene is a type of drug known as a selective estrogen receptor modulator (SERM) that is similar to the drug tamoxifen. A combination of bazedoxifene and estrogen taken orally has been used to control hot flashes. This study will look at hot-flashes, quality of life and breast changes in high-risk women taking the combination of drugs compared with women not taking the combination of drugs. Women will be selected at random to participate in the group receiving the drug and the group not receiving the drug. The study will involve breast imaging, blood tests and small sampling of breast tissue at the beginning and end of the study. 

Treating Recurrent or Metastatic Endometrial Cancer with an Immunotherapy in Combination with a PARP Inhibitor or a Chemotherapy Drug

https://www.facingourrisk.org/research-clinical-trials/study/235/treating-recurrent-or-metastatic-endometrial-cancer-with-an-immunotherapy-in-combination-with-a-parp-inhibitor-or-a-chemotherapy-drug


Treatment study for metastatic endometrial cancer

This study will determine the effectiveness of an immunotherapy called Avelumab, in treating recurrent or metastatic endometrial cancer. One group of participants will receive Avelumab, a second group of participants will receive the combination of Avelumab and Talazoparib, and a third group of participants will receive the combination of Avelumab and Axitinib. The effectiveness of the study drugs will be measured through tumor biopsies. NOTE: This study is no longer enrolling patients.

Research Opportunity for Previvors and their Romantic Partners

https://www.facingourrisk.org/research-clinical-trials/study/207/research-opportunity-for-previvors-and-their-romantic-partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

Researchers at the University of Kentucky are hoping to learn more about the relational experiences of individuals with hereditary breast cancer mutations who have navigated a double mastectomy while in a committed romantic relationship. They are particularly interested in the couples’ experience related to sexual intimacy before and after prophylactic surgical procedures. You do not have to live in Kentucky to participate. 

Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

https://www.facingourrisk.org/research-clinical-trials/study/198/studying-the-medication-olaparib-given-with-radium-223-for-advanced-prostate-cancer-with-bone-metastasis


People with castration-resistant prostate cancer with bone spread

This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones. 

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study)

https://www.facingourrisk.org/research-clinical-trials/study/199/young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors. 

BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

https://www.facingourrisk.org/research-clinical-trials/study/169/brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

This study seeks to interview individuals who come from families with high cancer risk and/or who have tested positive for BRCA 1/2 genetic mutation. We are also interested in individuals who may be contemplating BRCA 1/2 genetic testing; those who feel they lack access to genetic testing or who feel they lack information and social and medical support with regard to getting access to genetic testing; those who have been diagnosed with breast cancer who may be at high risk for a range of hereditary cancer. We are especially hoping to reach racially and ethnically diverse males and females whose experiences are often left out of research studies.

Cancer Experience Registry

https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer

Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/200/chemotherapy-immunotherapy-and-parp-inhibitor-for-the-treatment-of-metastatic-aggressive-variant-prostate-cancer-avpc

Treatment
Treatment in people with aggressive metastatic prostate cancer

This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). The research will compare the benefits of giving niraparib with or without cetrelimab, after treatment with chemotherapy.

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.

All of Us Research Program

https://www.facingourrisk.org/research-clinical-trials/study/197/all-of-us-research-program

Surveys, Registries, Interviews
Anyone age 18 or over

The All of Us Research Program is seeking one million people from across the U.S. to help build one of the most diverse health databases in history. We welcome participants from all backgrounds. People who join will share information about their health, habits, and what it’s like where they live. By looking for patterns, researchers may learn more about what affects people’s health.

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

Interview Study: Exploring Gender Diverse Experiences of Hereditary Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/186/interview-study-exploring-gender-diverse-experiences-of-hereditary-cancer-risk


People with elevated cancer risk who identify as trans* or nonbinary

Are you a gender diverse previvor or patient who would like to share your story? A Johns Hopkins genetic counseling student is conducting an interview study exploring gender diverse folks’ experiences of hereditary cancer care, with the aim of better educating providers about LGBTQ+ needs and concerns. We are conducting interviews over Zoom with individuals who qualify. If you are interested in participating, contact Sarah Roth at [email protected]. NOTE: This study is no longer enrolling people.

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

https://www.facingourrisk.org/research-clinical-trials/study/177/androgen-suppression-with-abiraterone-leuprolide-parp-inhibitor-and-stereotactic-radiotherapy-in-prostate-cancer-asclepius

Treatment
Newly diagnosed prostate cancer grade group 3-5

This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

https://www.facingourrisk.org/research-clinical-trials/study/195/inherited-cancer-registry-icare-contribute-to-research-while-staying-informed

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

ICARE is a registry of individuals interested in participating in inherited cancer research, through which data and samples are collected to contribute to research. Participants are also provided with ongoing research and clinical updates and informed about other research opportunities for which they might be eligible. Participants are recruited across the United States and beyond. There is no cost to participate, and all materials can be completed online.

Differences in Family Communication about Positive Genetic Test Results Between Asian Americans

https://www.facingourrisk.org/research-clinical-trials/study/208/differences-in-family-communication-about-positive-genetic-test-results-between-asian-americans

Surveys, Registries, Interviews
Interview for Asian Americans with a mutation in BRCA1, BRCA2, ATM, CHEK2, PALB2 or other gene linked to breast or ovarian cancer risk

This study aims to explore family communication differences across Asian American families  about testing positive for an inherited mutation in BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53 or another gene linked to hereditary breast and/or ovarian cancer. Participants will complete a 10–15-minute initial intake survey to confirm eligibility. Eligible participants will then be contacted to schedule a 30-45-minute-long interview over Zoom to explore these topics. After completion of the interview, participants will be entered into a raffle for two $50 Visa gift cards. There are no costs associated with participation. NOTE: This study is closed. 

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

This study is researching whether adding the immunotherapy drug Pembrolizumab (Keytruda) to the PARP inhibitor Olaparib (Lynparza) works better than olaparib alone in treating people with metastatic pancreatic cancer who also have an inherited BRCA1 or BRCA2 mutation.  

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/202/physical-activity-promotion-for-breast-and-endometrial-cancer-survivors


Exercise study for breast or endometrial cancer survivors

This study is looking at whether messaging and coaching can increase activity level and how moderate-to-vigorous activity improves symptoms and quality-of-life in women diagnosed with breast or endometrial cancer. NOTE: This study is no longer enrolling. 

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum

Treatment
Advanced endometrial cancer

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.

Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family

https://www.facingourrisk.org/research-clinical-trials/study/185/survey-about-endometrial-cancer-risk-and-risk-reducing-surgery-for-women-with-a-brca12-mutation-or-mutation-in-the-family


Women with a BRCA mutation or from a family with a BRCA mutation

Researchers at the Mayo Clinic, McGill University and FORCE are conducting a survey of women with a BRCA1/2 mutation, or who come from a family with a known BRCA mutation but tested negative, or have not had testing. Our goal is to learn about the information needs and decisions made related to endometrial cancer risk. https://tinyurl.com/BRCAMUTATION. NOTE: This study is closed for enrollment. 

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Treatment
Advanced solid tumors

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine. 

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations


Advanced solid tumors

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/144/atorvastatin-aspirin-for-colorectal-cancer-prevention-for-people-with-lynch-syndrome


This study will look at how well atorvastatin (a cholesterol lowering agent) works with or without aspirin in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

Developing a Test for the Detection of Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/137/developing-a-test-for-the-detection-of-ovarian-cancer

Prevention

The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors


Advanced solid tumors

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

Assessing Decisions about Uterine and Ovarian Cancer Prevention by People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/224/assessing-decisions-about-uterine-and-ovarian-cancer-prevention-by-people-with-lynch-syndrome

Surveys, Registries, Interviews
Online survey for people with Lynch syndrome

This study is seeking information about the personal experiences of uterine and ovarian cancer prevention and screening for people with Lynch syndrome. An online survey will allow participants to share their experiences which will ultimately help medical practitioners be more aware about the wants, needs, and decision-making strategies used by people with Lynch syndrome to preserve their gynecological health.

Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study

Treatment

This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation

Prevention

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

EnergyPoints: A Mobile App Guiding Use of Acupressure for Cancer-related Fatigue and Sleep Disturbances

https://www.facingourrisk.org/research-clinical-trials/study/184/energypoints-a-mobile-app-guiding-use-of-acupressure-for-cancer-related-fatigue-and-sleep-disturbances

Quality of Life
Anyone diagnosed with cancer experiencing fatigue

This study is looking at the use of acupressure to manage cancer-related fatigue and sleep disturbances. EnergyPoints is an app that teaches users how to self-administer acupressure, to manage fatigue and sleep disturbances related to cancer. The purpose of this research study is to learn from participants’ experiences using EnergyPoints, while they wear a fitness tracker to measure activity and sleep.

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations

Treatment

This study will look at how well the drug olaparib works in treating people who have been diagnosed with biliary tract (bile duct) cancer that has spread to other places in the body and who also have an inherited or tumor mutation in certain genes, including ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others.  

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. 

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

https://www.facingourrisk.org/research-clinical-trials/study/221/adding-parp-inhibitor-to-enzalutamide-to-treat-men-with-metastatic-prostate-cancer-that-is-resistant-to-anti-androgen-therapy


Treatment study for men with metastatic prostate cancer

This study is testing the effectiveness of adding a type of targeted therapy known as a PARP inhibitor to androgen-deprivation therapy for men with metastatic prostate cancer that has become resistant to standard androgen deprivation therapy.

 

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw

Treatment
People with metastatic colorectal cancer that is MSI-High

The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy. 

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy

Treatment

This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.

 

Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/216/studying-types-of-therapy-for-coping-with-fear-of-recurrence-among-breast-cancer-survivors


People with stage 1-3 breast cancer who completed treatment within 5 years of enrollment

Fear of cancer recurrence (FCR) is a common problem for breast cancer survivors. This study will test the effectiveness of three types of online, group therapy for breast cancer survivors with FCR. 

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/119/a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation

Surveys, Registries, Interviews

Women with a BRCA1 or BRCA2 mutation are at higher risk of developing breast and/or ovarian cancer compared to women in the general population. There are various options available to these women to help reduce or manage these risks, including preventive surgery. We are conducting an important new study to examine and understand cancer prevention decisions and outcomes in these women.

Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)

https://www.facingourrisk.org/research-clinical-trials/study/143/nivolumab-vs-placebo-combined-with-neoadjuvant-chemotherapy-adjuvant-endocrine-therapy-for-high-risk-er-her2-negative-breast-cancer-checkmate-7fl


Newly-diagnosed, non-metastatic, ER-positive, HER2-negative breast cancer

CA209-7FL: The purpose of a clinical trial is to look at whether the study drug, nivolumab, works in combination with neoadjuvant chemotherapy and adjuvant endocrine (hormone) therapy. The study will look at the safety profile of these study drug combinations and how well your body tolerates them. NOTE: This study is no longer enrolling patients. 

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer

Prevention

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/120/the-risk-factor-analysis-of-hereditary-breast-and-ovarian-cancer-in-women-with-brca1-brca2-or-palb2-mutations

Surveys, Registries, Interviews

Those who carry the BRCA1, BRCA2 or PALB2 gene mutations experience a higher lifetime risk of developing breast and ovarian cancer, but we need to know more about the other genetic and non-genetic factors that may also influence risk. This study follows women with these gene mutations over time, striving to build the evidence we need to help them and others make better decisions to protect their health.

Diagnosis of Breast Cancer in Young Women - Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/113/diagnosis-of-breast-cancer-in-young-women-share-your-story

Surveys, Registries, Interviews

Researchers from the University of Illinois, Chicago Cancer Center invite breast cancer survivors who were diagnosed under the age of 45 to share their diagnosis stories. You will be asked to use your own words to share your experience on an online questionnaire. 

Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair

https://www.facingourrisk.org/research-clinical-trials/study/203/abirateroneprednisone-and-olaparib-alone-or-in-combination-for-treatment-of-metastatic-castration-resistant-prostate-cancer-with-mutations-related-to-dna-repair

Treatment
Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene

This study is comparing three different treatments for men with metastatic castration-resistant prostate cancer, (mCRPC) who also have an inherited mutation or a tumor mutation in a gene that affects DNA damage repair. The study is open to men with inherited mutations found on genetic testing or tumor mutations in one of the following genes: ATM, BRCA1, BRCA2, FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A.

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

https://www.facingourrisk.org/research-clinical-trials/study/68/olaparib-expanded-treating-metastatic-breast-cancer-in-people-without-gbrca-mutations


Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing. 

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations

Treatment

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

https://www.facingourrisk.org/research-clinical-trials/study/209/treatment-for-metastatic-castration-sensitive-prostate-cancer-and-inherited-or-tumor-mutations-in-dna-damage-repair-genes-amplitude


Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L. NOTE: This study is no longer enrolling patients. 

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach

Treatment

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit  the E-Reach registration page. 

Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results

https://www.facingourrisk.org/research-clinical-trials/study/211/exploring-the-fertility-preservation-needs-of-individuals-with-positive-genetic-test-results


Survey and video interview for people who tested positive for an inherited mutation

The goal of this study is to identify if there is a need for more specialized providers, specifically genetic counselors, to meet the needs of patients regarding fertility preservation and family planning prior to cancer treatment or preventative surgery. We hope to identify the appropriate setting and timeline for these services to streamline and enhance comprehensive patient care for patients with a hereditary breast or gynecologic cancer variant.

Metastatic Prostate Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/70/metastatic-prostate-cancer-project

Surveys, Registries, Interviews

The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with advanced and/or metastatic prostate cancer. Patients can join online and participate by sharing their medical information and samples. The goal of the project is to generate a comprehensive database that will be shared with the entire research community to accelerate discoveries in prostate cancer.

The Metastatic Breast Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/60/the-metastatic-breast-cancer-project

Surveys, Registries, Interviews

The Metastatic Breast Cancer Project is a patient-partnered initiative that directly engages patients across the US & Canada to transform our understanding of metastatic breast cancer. Patients participate by sharing their medical information, tumor samples, and their voices, partnering with the project team to accelerate discoveries. There is no cost to participate and only minimal effort is required to have a major impact.
 

Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/215/factors-influencing-reproductive-decision-making-in-individuals-with-a-brca1-or-brca2-gene-mutation


Survey for people with a BRCA1 or BRCA2 mutation

This study will survey individuals with a mutation in the BRCA1 or BRCA2 gene. We are seeking experiences and opinions of individuals regarding childbearing and reproductive choices. This will allow healthcare professionals, especially genetic counselors, to learn about what information is needed due to psychosocial and medical factors. The survey is approximately 25 minutes long to complete and is available online.

A Pancreatic Cancer Screening Study for High Risk Individuals

https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people

Prevention

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident

Prevention

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.

Interview Study about Barriers to Genetic Testing of Family Members in Latin America

https://www.facingourrisk.org/research-clinical-trials/study/212/interview-study-about-barriers-to-genetic-testing-of-family-members-in-latin-america

Surveys, Registries, Interviews
People with a hereditary cancer gene mutation and relatives living in Latin America

We are interviewing people who identify as Hispanic/Latinx/e with a genetic mutation associated with hereditary cancer and close family members who live in Latin America. This research study will describe genetic testing barriers and the communication of genetic risk to family members living in a Latin American country. The goal of this study is to improve the support that cancer genetic counselors can offer to individuals and their international family members. NOTE: This study is no longer enrolling. 

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/63/genetic-testing-for-men-with-metastatic-prostate-cancer-gentlemen-study

Treatment

The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

 

Connect My Variant

https://www.facingourrisk.org/research-clinical-trials/study/90/connect-my-variant

Surveys, Registries, Interviews

Researchers at the University of Washington (UW) are recruiting participants with known inherited mutation.  We aim to help participants talk to relatives (both immediate and distant) about their family history and genetic test results, to connect them with others who have the same variant, and to their family trees together.  The study provides tools and resources to help at-risk relatives get genetic testing through their own local doctors.

Genomic Services Research Program Study for People with Unexpected Genetic Results

https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results

Prevention

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)

https://www.facingourrisk.org/research-clinical-trials/study/86/talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job

Quality of Life

The goal of this study is to improve a tool that helps cancer patients navigate work-related issues. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs. The app – called TEAMWork (Talking to Employers And Medical staff about Work) – provides advice for patients who need to talk to their employers about treatment or their medical team about work. Researchers want patient feedback on what aspects of the app work well and what can be better.  

Breast Cancer Treatment in Women with PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/85/breast-cancer-treatment-in-women-with-palb2-mutations

Surveys, Registries, Interviews

The PALB2 Study is an international research study to better understand breast cancer treatment among women with a PALB2 gene mutation. Participants are asked to complete online or paper study questionnaires (every two years for 10 years) and share their family history, medical, and genetics records.

 

Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)

https://www.facingourrisk.org/research-clinical-trials/study/84/ellies-project

Quality of Life

ELLIE’s Project is designed to look at factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life-time.

ELLIE’s Project aims to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.

The web-based survey can be accessed through this hypterlink. 

Then entering code: PYCYHXD3A

Combination Drugs for Treating Metastatic Castration-resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair

https://www.facingourrisk.org/research-clinical-trials/study/206/combination-drugs-for-treating-metastatic-castration-resistant-prostate-cancer-with-tumor-mutation-that-affect-dna-repair

Treatment
Treatment study for men with metastatic castration-resistant prostate cancer

The goal of this study is to compare the effectiveness of three different drug combinations to treat men with metastatic castration-resistant prostate cancer (mCRPR), who also have a mutation in a gene that affects DNA repair found through tumor testing. 

 

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment


The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

Zoom Interviews to Explore Ideas about Long-Term Follow-Up Cancer Genetic Counseling

https://www.facingourrisk.org/research-clinical-trials/study/213/zoom-interviews-to-explore-ideas-about-long-term-follow-up-cancer-genetic-counseling


Interviews with adults that have recently met with a cancer genetic counselor in the U.S., regardless of genetic testing outcome

This study aims to explore perceptions of patients and genetic counselors about long-term follow-up in cancer genetic counseling, including if and how patients would like additional follow-up with a genetic counselor beyond the pre- and post-test counseling session. If you wish to participate, email the student investigator to schedule a voluntary 30–60-minute Zoom interview. All information will be de-identified. There are no costs associated with participation. NOTE: This study is no longer enrolling. 

Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

https://www.facingourrisk.org/research-clinical-trials/study/33/identification-and-analysis-of-families-with-genetic-susceptibility-to-cancer-registry

Surveys, Registries, Interviews

 

The research laboratory at the Abramson Cancer Center is studying genetic sources of cancer risk and currently has one of the largest collections (also called a registry) of families with known or suspected risk in the world. A number of research projects are performed in collaboration with this registry. Research participants receive a numerical identification number that protects their privacy. Collaborating centers do not have access to personal identifiers such as names and dates of birth because only the numerical identifiers are shared.

For more information visit basser.org/researchregistry.

 

UCLA Research Study: Zoom Interviews to Learn from Asian Americans Living with Metastatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/174/ucla-research-study-zoom-interviews-to-learn-from-asian-americans-living-with-metastatic-cancer


Asian Americans with metastatic cancer of any type

We would like to invite you to share your experiences to help improve the quality of life for Asian Americans diagnosed with metastatic cancer. NOTE: This study is no longer enrolling. 

Pancreatic Cancer Early Detection Program

https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection

Prevention

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

Metastatic Pancreatic Cancer in US

https://www.facingourrisk.org/research-clinical-trials/study/194/metastatic-pancreatic-cancer-in-us


People with metastatic pancreatic cancer and their caregivers

Global Patients along with IQVIATM, a worldwide healthcare consulting firm, is currently conducting a research study, to better understand the experience of patients and/or caregivers of patients living with metastatic pancreatic cancer.

Interviews for People With a Genetic Test Result That was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/193/interviews-for-people-with-a-genetic-test-result-that-was-later-reclassified


People with a genetic test result that was later reclassified

Researchers at MD Anderson Cancer Center are conducting telephone interviews with individuals who have received modified (also known as reclassified or amended) genetic test results in any cancer related gene. We are interested in learning about the experience of receiving a modified test result and decisions made. 

Studying Crowdfunding for Cancer

https://www.facingourrisk.org/research-clinical-trials/study/187/studying-crowdfunding-for-cancer


Cancer survivors who have used crowdfunding to help cover cancer-related costs

This is a study on how the practice of crowdfunding affects the experience of having cancer. With the support of the National Science Foundation (NSF award #2021152), the researcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. earcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. For more information, visit studyingcrowdfundingforcancer.net. If you'd like to share your story in an interview, please email Martha Lincoln at [email protected].

Survey: Making Decisions about Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/189/survey-making-decisions-about-genetic-testing


Survey for adults who have had genetic testing for inherited cancer risk through a doctor

You are invited to participate in an anonymous online survey about your decision to do genetic testing and how you dealt with the uncertainty of the outcome. The online survey includes a newly developed Uncertainty Management Scale (UMS) based on our years of prior uncertainty research. Knowing more about how people manage uncertainty may be helpful to society. You will be compensated $10 for completing the survey. This study is no longer enrolling. 

Interview Study about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/191/interview-about-hispaniclatino-community-experiences-accessing-genetic-testing-for-hereditary-cancer-risk


Hispanic/Latino people with a personal diagnosis of cancer or a family history of cancer

This study is looking at how to improve access to genetic testing among Hispanic/Latino populations in the U.S. We are conducting interviews with people in the Hispanic/Latino community who have either received genetic testing for hereditary cancer risk, or who have a family history of hereditary cancer and/or cancer diagnosis. This study could help develop policy options to inform how to improve access to genetic testing. Email Amanda Gutierrez at [email protected] if you are interested in participating. NOTE: This study is no longer enrolling.

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

https://www.facingourrisk.org/research-clinical-trials/study/179/targeted-therapy-rp-3500-alone-or-in-combination-with-talazoparib-or-gemcitabine-in-advanced-solid-tumors-with-dna-damage-repair-mutations-tresr-study


Advanced solid tumors

This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.

ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/155/atr-inhibitor-plus-niraparib-study-in-advanced-solid-tumors-and-ovarian-cancer


Advanced ovarian cancer or other solid tumors

This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.

A Survey on Health Behaviors for Women with BRCA1/2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/190/a-survey-on-health-behaviors-for-women-with-brca12-mutations


Survey for women with a BRCA1 or BRCA2 mutation

Researchers in the National University of Ireland, Galway are looking for people to take part in a survey on BRCA1/2 alteration carriers and health behaviours. The once-off survey asks questions about how you cope and what you think about health behaviours. Note: This study is closed to enrollment.

Survey: Medical Records to Save After a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/162/survey-medical-records-to-save-after-a-cancer-diagnosis


Adults with cancer

In less than 5 minutes, learn which medical records are important to keep after a cancer diagnosis, why they are important to save, and ideas of how to keep them for you and your family.  The study has been IRB-approved by UC Irvine and is available in English and Spanish!  Note: This study is now closed to enrollment.

Investigating BRCA Previvors’ Utilization of Social Media for Health Decision Making and Social Support

https://www.facingourrisk.org/research-clinical-trials/study/173/investigating-brca-previvors-utilization-of-social-media-for-health-decision-making-and-social-support


Women with a BRCA1 or BRCA2 mutation who have never had cancer

This study investigates why women share aspects of their previvorship identity on social media platforms. We are interviewing women above 18 years old, who carry known pathogenic variants in BRCA1 or BRCA2, and share their previvor journey on social media platforms like Instagram, Facebook, Twitter, and TikTok at least once every other week. We are conducting anonymous interviews over Zoom with women who qualify. If you are interested, contact Mariah Wellman at [email protected]. NOTE: This study is no longer enrolling people. 

Survey: How Willing are You to Participate in Different Types of Clinical Trials for the Prevention of Breast Cancer?

https://www.facingourrisk.org/research-clinical-trials/study/188/survey-how-willing-are-you-to-participate-in-different-types-of-clinical-trials-for-the-prevention-of-breast-cancer


This study looks at why women at an increased risk of developing breast cancer are interested or uninterested in participating in breast cancer prevention clinical trials. The study consists of a 10-15 minute (max) anonymous questionnaire that asks hypothetical questions about participating in clinical trials with various study designs. This study’s findings may be used to better inform how to best design clinical trials aimed at the prevention of a breast cancer in the future. NOTE: This study is no longer enrolling.

Survey for Caregivers of Relatives in Families with an Inherited Mutation Linked to Cancer

https://www.facingourrisk.org/research-clinical-trials/study/150/survey-for-caregivers-of-relatives-in-families-with-an-inherited-mutation-linked-to-cancer


This anonymous survey is being conducted by researchers at the National Human Genome Research Institute of the National Institutes of Health, in collaboration with Facing Our Risk of Cancer Empowered (FORCE). The goal of this survey is to help researchers understand the caregiving experiences of families affected by hereditary cancer. By sharing your experience with us, you can help us develop more resources to improve the experience of future family caregivers.  NOTE: THIS STUDY IS NO LONGER ENROLLING.

 

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

https://www.facingourrisk.org/research-clinical-trials/study/115/tucatinib-plus-trastuzumab-in-patients-with-her2-colorectal-cancer-mountaineer

Treatment

This is a study for people who have been diagnosed with HER2-positive (HER2+) metastatic colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

Using ctDNA Blood Test to Screen for Cancer DNA after Treatment for Early-Stage TNBC and/or an Inherited or Tumor BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

https://www.facingourrisk.org/research-clinical-trials/study/170/screening-for-cancer-dna-in-the-blood-after-treatment-for-early-stage-tnbc-andor-a-brca-mutation-followed-by-study-comparing-niraparib-with-placebo-for-people-with-cancer-dna-found-in-their-blood-zest


Early-stage TNBC or early-stage breast cancer with a BRCA mutation

This study will enroll people with early-stage triple negative breast cancer or people with an inherited or acquired BRCA1 or BRCA2 mutation who have completed treatment (or are still in treatment with hormone therapy) for screening using a blood test known as circulating tumor DNA (ctDNA). Individuals who test positive for ctDNA may be eligible to participate in a randomized study to receive the PARP inhibitor, niraparib or a placebo and undergo close monitoring with imaging (CT scans). The study will look at the safety and efficacy of niraparib plus monitoring compared with placebo plus monitoring for people who test positive for cancer cells in their blood but who have no evidence of cancer recurrence. NOTE: This study is no longer enrolling. 

A National Survey to Share the Voices of Ovarian Cancer Caregivers

https://www.facingourrisk.org/research-clinical-trials/study/167/a-national-survey-to-share-the-voices-of-ovarian-cancer-caregivers


Caregivers to people with ovarian cancer

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer.  The research hopes to identify areas for improvement in supporting the lives of people who care for patients living with ovarian cancer. By taking part in the survey your views, alongside those of other caregivers of women living with ovarian cancer will be heard. This will help generate the scientific evidence required to ensure healthcare professionals and other healthcare supporting bodies have a deep understanding about what it is like to live with advanced ovarian cancer and can help provide them with the tools to support patients, caregivers, and their families. NOTE: This survey is closed to enrollment.

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib

https://www.facingourrisk.org/research-clinical-trials/study/133/treating-metastatic-pancreatic-colorectal-gastroesophageal-or-biliary-cancer-with-chemotherapy-and-rucaparib


Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer

This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized). NOTE: This study is no longer enrolling patients. 

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/152/talazoparib-in-treating-patients-with-recurrent-advanced-or-metastatic-cancers-and-inherited-or-acquired-gene-mutations


This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes. NOTE: This study is no longer enrolling patients. 

Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

https://www.facingourrisk.org/research-clinical-trials/study/166/dostarlimab-plus-carboplatin-paclitaxel-versus-placebo-plus-carboplatin-paclitaxel-for-recurrent-or-primary-advanced-endometrial-cancer-ruby


Metastatic endometrial cancer

This study for people with Stage III or Stage IV endometrial cancer will look at how well the combination of an immunotherapy plus targeted therapy and chemotherapy works compared with chemotherapy alone.  NOTE: This study is no longer enrolling people. 

TALAPRO-2: A study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

https://www.facingourrisk.org/research-clinical-trials/study/98/talapro-2-a-study-assessing-the-study-drug-enzalutamide-vs-placebo-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-dna-damage-repair-ddr-deficiency


The TALAPRO-2 study is assessing whether the study drug is safe and effective when given in combination with enzalutamide as a treatment option for men with metastatic castration-resistant prostate cancer and DDR deficiency. NOTE: This study is no longer enrolling patients. 

A National Survey to Share the Voice and Treatment Preferences of Ovarian Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/163/a-national-survey-to-share-the-voice-and-treatment-preferences-of-ovarian-cancer-patients


Ovarian cancer

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer and preference for different ways of taking medication.  The research hopes to identify areas for improvement in supporting the lives of patients living with ovarian cancer and the people that care for them after 1st surgery and chemotherapy.  NOTE: This survey is closed to enrollment.

Interview: Understanding the Experiences of Black Women after Cancer Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/160/understanding-the-experiences-of-black-women-after-cancer-genetic-testing


Black women who have tested positive for an inherited mutation

We are looking to interview Black women who have received a positive result in a cancer-associated genetic test. We want to hear your story. This research will look at Black women's experiences with cancer genetic testing. If you decide to take part in the study, you would participate in an approximately hour-long phone interview. Participants will be compensated for their time with a $20 gift card. Contact Malika Sud at [email protected] for more information or to participate. NOTE: This study is now closed. 

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/147/olaparib-palbociclib-and-fulvestrant-for-brca-associated-erpr-positive-her2-negative-metastatic-breast-cancer


The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

Fear of Recurrence, Adversity, and Pain

https://www.facingourrisk.org/research-clinical-trials/study/161/fear-of-recurrence-adversity-and-pain


We are investigating the relation of adversity, pain, and fear of cancer recurrence among adult cancer survivors. Participation involves completing a 30-minute computerized survey online from your home computer. No compensation is being offered for participation in this research study.

Enhancing Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/142/breast-and-ovarian-cancer-education-research-for-african-americanblack-and-latina-women


Researchers are conducting a study to test how well education materials increase use knowledge about hereditary cancer risk. Participants will watch 90 minutes of educational videos and complete 2 short surveys. In all, this will take approximately 3 hours to complete over a two-week period. Everything will be completed over the phone or online. Compensation will be provided for participation. NOTE: This study is no longer enrolling participants. 

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

https://www.facingourrisk.org/research-clinical-trials/study/135/treating-metastatic-pancreatic-cancer-with-an-inherited-or-tumor-brca12-or-palb2-mutation-with-niraparib-and-dostarlimab


This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.

AMPLIFY: a new online weight loss study specifically for cancer survivors!

https://www.facingourrisk.org/research-clinical-trials/study/139/amplify-a-new-online-weight-loss-study-specifically-for-cancer-survivors


AMPLIFY is a nation-wide, web-based diet and exercise study recruiting overweight survivors of early stage breast, prostate, ovarian, renal, colorectal and endometrial cancer and multiple myeloma. This study is enrolling qualified cancer survivors age 50 and older who are interested in becoming more active, eating better and losing weight.

Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117

https://www.facingourrisk.org/research-clinical-trials/study/159/treating-advanced-solid-tumors-in-people-with-inherited-pten-mutations-using-the-investigational-drug-tas-117


People with advanced cancer and an inherited PTEN mutation

This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors). 

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

https://www.facingourrisk.org/research-clinical-trials/study/148/olaparib-plus-pembrolizumab-versus-chemotherapy-plus-pembrolizumab-after-first-line-treatment-in-advanced-triple-negative-breast-cancer-keylynk-009


This study will look at how people with advanced triple-negative breast cancer (TNBC) respond to different combinations of drugs. During an initial study period participants will receive a combination of chemotherapy and immunotherapy drugs. Participants with stable cancer or an improvement will be able to continue with the study. Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead immunotherapy plus a type of targeted therapy known as a PARP inhibitor during the follow-up period.  NOTE: This study is no longer enrolling patients. 

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/114/pembrolizumab-plus-lenvatinib-versus-chemotherapy-for-endometrial-cancer

Treatment

The purpose of this study is to compare the effectiveness of using a combination of the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy lenvatinib (Lenvima) in women with Stage III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment

TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/125/talave-talazoparib-followed-by-combination-of-talazoparib-and-avelumab-in-advanced-breast-cancer


TALAVE is a study for patients who have advanced or metastatic breast cancer that will not be cured by treatment with surgery or radiotherapy, and either have a BRCA1/2 mutation (germline or somatic) or have triple negative breast cancer who are not known to have a BRCA1/2 mutation. The goal of TALAVE is to look at whether giving talazoparib alone followed by talazoparib with avelumab is a safe and effective treatment for advanced breast cancer. THIS STUDY IS NO LONGER ENROLLING.

COVID-19 Breast Cancer Care Survey

https://www.facingourrisk.org/research-clinical-trials/study/145/covid-19-breast-cancer-care-survey


The purpose of this research study is to learn about how the COVID-19 pandemic has affected cancer care and quality of life in breast cancer survivors. Participants will complete an online survey and some women will be invited to participate in an online interview to learn more about their cancer treatment experiences during the pandemic. NOTE: This study is no longer enrolling. 

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

https://www.facingourrisk.org/research-clinical-trials/study/146/omega-3-fatty-acids-in-colorectal-cancer-crc-prevention-in-patients-with-lynch-syndrome-colyne


This study looks at how well omega-3 fatty acid ethyl esters (generic Lovaza) work in preventing colorectal cancer in patients with Lynch syndrome. Omega-3 fatty acids work by decreasing inflammation, or swelling, in the body, and suppressing certain chemicals in the body that are known to cause cancer. The addition of omega-3 fatty acids to patients' diets may help decrease colon inflammation or suppress cancer-causing chemicals in the body. NOTE: This study is no longer enrolling people. 

Research Study to Help Improve Family Communication About Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/118/research-study-to-help-improve-family-communication-about-inherited-brca1-or-brca2-mutations


The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone.  Participants will be asked to complete a total of 3 surveys.  Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable.  Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials). 

You can get more information or ask to participate in the study by sending an email to: [email protected].

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/124/phase-1-study-of-oral-drug-pmd-026-in-people-with-metastatic-breast-cancer-and-metastatic-triple-negative-breast-cancer


PMD-026 is a study for people who have been diagnosed with metastatic triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC. NOTE: This study is no longer enrolling. 

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/111/addition-of-pembrolizumab-to-radiation-treatment-for-newly-diagnosed-early-stage-msi-high-endometrial-cancer


The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High. This study is no longer enrolling.

A Study of EDP1503 in Patients With Colorectal or Triple Negative Breast Cancer or Cancer That Came Back After Treatment with a Checkpoint Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/116/a-study-of-edp1503-in-patients-with-colorectal-cancer-breast-cancer-or-checkpoint-inhibitor-relapsed-tumors

Treatment

Medicines that affect bacteria in the stomach and intestines may assist immunotherapy agents like pembrolizumab (Keytruda) in treating cancer. This study will look at the effect of a drug, EDP1503 on enhancing the anti-cancer response when used with pembrolizumab, in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, or cancers that have recurred after a type of immunotherapy known as an immune checkpoint inhibitor. NOTE: This this study is no longer enrolling patients. 

RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer

https://www.facingourrisk.org/research-clinical-trials/study/192/restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer


People with stage 1-3 cancer

Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

https://www.facingourrisk.org/research-clinical-trials/study/58/parp-inhibitor-for-metastatic-prostate-cancer-with-dna-repair-defects

Treatment

This is a phase II study looking at different treatment combinations for men with metastatic, castration resistant prostate cancer (mCRPC) to see which is most effective for improving progression free survival (keeping the cancer from progressing). The study will include testing for genes within the tumor to determine eligibility for the study. 

Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations or defects will be randomly assigned to one of the treatment arms of the study. Patients with tumors that have mutations in other DNA repair genes including FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A will be assigned to Arm IV with single agent olaparib. NOTE: This study is now closed. 

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/132/mobile-mindfulness-meditation-intervention-to-improve-neuropathy-in-cancer-survivors


Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts cancer-related neuropathy. We are asking people who have been diagnosed with cancer, have finished primary treatment and are experiencing neuropathy if they would like to use a mobile app for mindfulness meditation to see if it helps their neuropathy.  

Interested participants will be asked to follow the link for either anxiety OR neuropathy and to participate in only one of the studies, one time only. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)

https://www.facingourrisk.org/research-clinical-trials/study/136/niraparib-ipilimumab-or-nivolumab-in-pancreatic-cancer-that-has-not-progressed-after-platinum-chemotherapy-parpvax


The purpose of this study is to look at the effectiveness, safety, and anti-cancer activity of the drug Niraparib combined with one of two immunotherapy agents: Ipilimumab or Nivolumab on patients with locally advanced or metastatic pancreatic cancer.  Patients in this study must also have previously received Platinum-based chemotherapy without evidence of disease progression.  NOTE: This study is no longer enrolling patients. 

Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/130/parenting-adolescent-aged-children-while-managing-a-parental-cancer-diagnosis-share-your-story


The study explores how families faced with a parental cancer diagnosis communicate, or why they choose not to communicate, with their children about the cancer diagnosis, treatments, and other related topics. At least one family member (diagnosed parent or non-diagnosed parent) is asked to participate, but more than one member can sign up to be interviewed. NOTE: This study is no longer enrolling people. 

Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/131/mobile-mindfulness-meditation-intervention-for-cancer-survivors


Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts different areas of well-being in cancer survivors – namely, anxiety and cancer-related neuropathy. We are asking people who have been diagnosed with cancer and finished primary treatment if they would like to use a mobile app for mindfulness meditation to see if it impacts anxiety.  

Interested participants will be asked to follow the link for anxiety. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors

https://www.facingourrisk.org/research-clinical-trials/study/105/nous-209-genetic-vaccine-for-the-treatment-of-msi-h-colorectal-gastric-and-gastro-esophageal-junction-tumors

Treatment
Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors

The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR. Participants will receive the vaccine in combination with the immunotherapy drug Keytruda (pembrolizumab). 

A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

https://www.facingourrisk.org/research-clinical-trials/study/17/triton3-rucaparib-vs-physician-choice-for-castration-resistant-prostate-cancer

Treatment

The purpose of Triton3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency, respond to treatment with the PARP inhibitor rucaparib compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. NOTE: This study is no longer enrolling patients. 

Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/108/prostate-cancer-genetic-risk-experience-and-support-study-progress


Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) is a national, patient-driven registry for any male who has undergone or is currently undergoing genetic testing for prostate cancer. Note: This study is no longer enrolling. 

 

A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (QUILT-3.055)

https://www.facingourrisk.org/research-clinical-trials/study/106/combination-immunotherapies-in-patients-who-previously-received-immune-checkpoint-inhibitors-quilt-3055

Treatment

Immune checkpoint inhibitors immunotherapy drugs that allow the immune system to find and destroy cancer cells.

This study will use a combination of immunotherapies in people who's cancer got worse after treatment with a PD-1 or PD-L1 immune checkpoint inhibitor. NOTE: This study is no longer recruiting.

Safety and Efficacy of Olaparib Combined with Agents Targeting DNA Damage Repair Compared to Olaparib Alone

https://www.facingourrisk.org/research-clinical-trials/study/104/olaparib-combined-with-agents-targeting-dna-damage-repair-compared-to-olaparib-alone

Treatment

The purpose of this study is to assess the efficacy and safety of treatment with the PARP inhibitor, olaparib combined with the drug Ceralasertib compared with olaparib alone for patients with Triple-Negative Breast Cancer.

NOTE: This study is no longer enrolling patients. 

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

https://www.facingourrisk.org/research-clinical-trials/study/77/studying-a-combination-of-immunotherapies-and-biomarker-for-advanced-solid-tumors

Treatment

This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. NOTE: This study is no longer enrolling.

A Study of Nivolumab in Selected Uterine Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/110/a-study-of-nivolumab-in-selected-uterine-cancer-patients


The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer. 

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.  NOTE: This study is no longer enrolling. 

GENetic Education Risk Assessment and TEsting Study (GENERATE)

https://www.facingourrisk.org/research-clinical-trials/study/69/generate


The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.

This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires. Note: This study is no longer enrolling patients.

 

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

https://www.facingourrisk.org/research-clinical-trials/study/66/parp-inhibitor-alone-or-plus-immunotherapy-for-advanced-brca-associated-breast-cancer


This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of the study is to look at whether giving the PARP inhibitor olaparib in combination with the immunotherapy atezolizumab improves outcomes for patients compared to olaparib alone.  NOTE: This study is no longer enrolling people.

 

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

https://www.facingourrisk.org/research-clinical-trials/study/107/combination-chemotherapy-with-or-without-atezolizumab-in-treating-patients-with-stage-iii-colon-cancer-and-deficient-dna-mismatch-repair


This study is no longer enrolling people. 

PHACT Study: Population Health and Cancer Testing

https://www.facingourrisk.org/research-clinical-trials/study/75/phact-study


NOTE: The PHACT study is no longer recruiting patients. 

Pilot Study of Denosumab in BRCA1 or BRCA2 Mutation Carriers Scheduling Risk-Reducing Salpingo-Oophorectomy

https://www.facingourrisk.org/research-clinical-trials/study/74/denosumab-in-brca1-or-brca2-mutation-carriers-scheduling-risk-reducing-salpingo-oophorectomy


The purpose of this study is to evaluate the effects of denosumab on ovarian cancer risk markers among premenopausal women with a BRCA1 or BRCA2 mutation, who are scheduled to undergo risk-reducing surgery to remove their ovaries and fallopian tubes. UPDATE: THIS STUDY HAS BEEN DISCONTINUED.

A Study in Hereditary Breast and Ovarian Cancer Families to Provide Men With Up-To-Date Information About the Personal Importance of Genetic Testing (GEM)

https://www.facingourrisk.org/research-clinical-trials/study/65/genetic-education-for-men-gem-study


The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative. NOTE: This study is no longer enrolling people. 

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate-9KD)

https://www.facingourrisk.org/research-clinical-trials/study/64/checkmate-9kd-for-men-with-metastatic-prostate-cancer

Treatment

CheckMate-9KD is a clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. The purpose of this study is to compare three different combination therapies, each containing a drug called nivolumab and another anti-cancer drug. All three combination therapies are considered investigational, which means that they are not currently approved to treat men with metastatic prostate cancer. The study doctors want to learn more about which therapy is most effective in treating metastatic prostate cancer. NOTE: This study is no longer enrolling. 

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

https://www.facingourrisk.org/research-clinical-trials/study/62/athena-rucaparib-and-nivolumab-for-maintenance-in-ovarian-cancer

Treatment

ATHENA is a study for women who are newly diagnosed with ovarian cancer. The goal of ATHENA is to look at whether giving maintenance therapy with different agents improves outcomes for women who have completed front-line treatment. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

https://www.facingourrisk.org/research-clinical-trials/study/59/decision-navigation-for-advanced-prostate-cancer-treatment-options-using-mhealth


Men with advanced prostate cancer face difficult choices for treatment because of the nature of their disease and having limited options. This study will test the use of an innovative Registered Nurse-Community Patient Navigator team delivered interactive mHealth decision aid for patients with advanced prostate cancer to help facilitate informed shared decisions about anti-cancer treatment that affects their quality of life. NOTE: This study is no longer enrolling. 

Safety and Efficacy of Olaparib Alone Or in Combination with Medication Targeting DNA Damaging Repair for Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/91/olaparib-plus-dna-damage-repair-targeted-therapy-for-metastatic-tnbc

Treatment

The purpose of this study is to learn the safety and effectiveness of the PARP inhibitor, olaparib as a single drug therapy compared with olaparib in combination with the new agent AZD6738 in patients with metastatic Triple-Negative Breast Cancer (TNBC).  NOTE: This study is no longer enrolling people. 

Olive Oil for High Risk Breast Cancer Prevention

https://www.facingourrisk.org/research-clinical-trials/study/97/olive-oil-for-high-risk-breast-cancer-prevention


This study will evaluate the effect of hydroxytyrosol, a component of olive oil, on breast density in women who are at high risk for developing breast cancer. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

 

Auricular Point Acupressure to Self-Manage Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/94/acupressure-to-self-manage-aromatase-inhibitor-musculoskeletal-symptoms-in-breast-cancer-survivors


Severe joint pain and muscle stiffness are common side effects of taking Aromatase Inhibitors.  Aromatase inhibitor musculoskeletal symptoms have a negative effect on a woman's physical function and quality of life. Auricular point acupressure uses stimulation applied to points on the ear without using needles. This study will look at and test auricular (ear) point acupressure to manage aromatase-inhibitor-caused joint pain and muscle stiffness in breast cancer survivors. 

Note: This study is no longer enrolling patients.

 

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)

https://www.facingourrisk.org/research-clinical-trials/study/92/a-study-to-evaluate-rucaparib-in-combination-with-other-anticancer-agents-in-patients-with-a-solid-tumor-seastar

Treatment

This study will look at how safe, effective and tolerable the oral PARP inhibitor Rucaparib is when used in combination with other anticancer agents in patients with advanced solid tumors, including triple-negative breast cancer, ovarian cancer or urothelial cancer. Note: This study has completed enrollment. 

Study of Safety and Effectiveness of Motiva® Breast Implants

https://www.facingourrisk.org/research-clinical-trials/study/80/study-of-safety-and-effectiveness-of-motiva-breast-implants

Quality of Life

Note: This study is no longer enrolling. 

The Women Choosing Surgical Prevention (WISP) Trial

https://www.facingourrisk.org/research-clinical-trials/study/4/women-choosing-surgical-prevention-wisp-trial


The WISP Study is closed to enrollment. Stay tuned for updates from FORCE on study results or new studies for ovarian cancer prevention. 

 

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

https://www.facingourrisk.org/research-clinical-trials/study/88/a-study-to-evaluate-rucaparib-in-patients-with-solid-tumors-and-with-deleterious-mutations-in-hrr-genes


The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.   NOTE: This study is no longer enrolling people.

A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

https://www.facingourrisk.org/research-clinical-trials/study/87/study-using-m6620-vx-970-an-atr-inhibitor-to-treat-solid-tumors

Treatment

This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation.  UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

https://www.facingourrisk.org/research-clinical-trials/study/83/immray-pancan-d-test-for-early-detection-of-pancreatic-cancer-in-high-risk-groups


This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions. ENROLLMENT HAS CLOSED FOR THIS STUDY!

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer (INTERVAL)

https://www.facingourrisk.org/research-clinical-trials/study/82/interval-intense-exercise-for-survival-in-men-with-metastatic-prostate-cancer


This study will determine if high intensity aerobic and resistance training (with supervised exercise) plus psychosocial support increases overall survival compared to psychosocial support alone (with self-directed exercise) in patients with metastatic castrate-resistant prostate cancer. NOTE: This study is no longer enrolling people. 

Patient-Driven Clinical Classification of Genetic VUS (Variants of Uncertain Significance)

https://www.facingourrisk.org/research-clinical-trials/study/28/find-my-variant


NOTE: This study is no longer enrolling. 

 

Making Genetic Testing Accessible (MAGENTA)

https://www.facingourrisk.org/research-clinical-trials/study/27/making-genetic-testing-accessible-magenta


The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer.  NOTE: This study has closed for enrollment.

IMProving Executive function Study

https://www.facingourrisk.org/research-clinical-trials/study/22/impres-improving-memory-after-rrso


Dr. C. Neill Epperson and her research team at the Penn Center for Women's Behavioral Wellness are studying the effects of a stimulant medication called Vyvanse® on memory and attention in women who had surgery to remove their ovaries to lower their risk for ovarian cancer (risk-reducing salpingo-oophorectomy or RRSO). NOTE: The study offers travel reimbursements and hotel accommodations for those eligible to participate. 

NOTE: This study is no longer enrolling people. 

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)

https://www.facingourrisk.org/research-clinical-trials/study/19/olympia-olaparib-adjuvant-therapy-for-brca-related-breast-cancer

Treatment

The OlympiA trial is the first major study to test a targeted therapy for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/10/aerobic-training-in-post-menopausal-women-at-high-risk-for-breast-cancer


In this study, researchers wanted to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women. 

Visit the study website for more information.

NOTE:  THIS STUDY ENROLLMENT HAS CLOSED

Prospective Registry Of MultiPlex Testing (PROMPT)

https://www.facingourrisk.org/research-clinical-trials/study/50/prompt


PROMPT is an online research registry for people who have had genetic panel testing (also known as multiplex testing) — a newer form of genetic testing that looks for mutations in several different genes at once. All genes on the panels have been linked to an increased risk of cancer, but some risks are better known than others.

The goal of the PROMPT Registry is to follow people with mutations or variants in genes on these panels, so that patients, physicians, and researchers can more clearly understand these lesser-known risks.

Serum Folate in Patients Treated with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/99/serum-folate-in-patients-treated-with-olaparib


This is a study looking at folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib (Lynparza) to treat their advanced ovarian or breast cancer. The main goal of this study is to measure how often and when folate deficiency is most likely to occur; and to learn more about whether giving folic acid supplements (vitamins) will help delay or avoid deficiency in these patients. Folate deficiency can cause side effects and lead to reduction or stopping of treatment with olaparib.  NOTE: This study is no longer enrolling people.

Talazoparib Beyond BRCA (TBB) Trial

https://www.facingourrisk.org/research-clinical-trials/study/35/talazoparib-beyond-brca-tbb-trial


The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. NOTE: This study is no longer enrolling people.

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/38/ariel4-rucaparib-and-recurrent-ovarian-cancer

Treatment

ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Additional Results on Clinicaltrials.gov
1000 results

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://classic.clinicaltrials.gov/show/NCT04703920)

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT ID: NCT05922930 (https://classic.clinicaltrials.gov/show/NCT05922930)

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
NCT ID: NCT05394259 (https://classic.clinicaltrials.gov/show/NCT05394259)

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
NCT ID: NCT04930783 (https://classic.clinicaltrials.gov/show/NCT04930783)

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT ID: NCT04117087 (https://classic.clinicaltrials.gov/show/NCT04117087)

Pembrolizumab + Infliximab for Metastatic Melanoma
NCT ID: NCT05034536 (https://classic.clinicaltrials.gov/show/NCT05034536)

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
NCT ID: NCT05057715 (https://classic.clinicaltrials.gov/show/NCT05057715)

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT ID: NCT03104439 (https://classic.clinicaltrials.gov/show/NCT03104439)

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT ID: NCT01638676 (https://classic.clinicaltrials.gov/show/NCT01638676)

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT ID: NCT04598009 (https://classic.clinicaltrials.gov/show/NCT04598009)

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
NCT ID: NCT05356117 (https://classic.clinicaltrials.gov/show/NCT05356117)

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
NCT ID: NCT06378047 (https://classic.clinicaltrials.gov/show/NCT06378047)

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT ID: NCT02870244 (https://classic.clinicaltrials.gov/show/NCT02870244)

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT ID: NCT03454035 (https://classic.clinicaltrials.gov/show/NCT03454035)

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://classic.clinicaltrials.gov/show/NCT04315233)

NeoVax With Nivolumab in Patients With Ovarian Cancer
NCT ID: NCT04024878 (https://classic.clinicaltrials.gov/show/NCT04024878)

Axitinib + Ipilimumab in Advanced Melanoma
NCT ID: NCT04996823 (https://classic.clinicaltrials.gov/show/NCT04996823)

War on Melanoma™ Public Health & Education Campaign
NCT ID: NCT04611568 (https://classic.clinicaltrials.gov/show/NCT04611568)

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
NCT ID: NCT05373823 (https://classic.clinicaltrials.gov/show/NCT05373823)

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
NCT ID: NCT04339140 (https://classic.clinicaltrials.gov/show/NCT04339140)

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://classic.clinicaltrials.gov/show/NCT05523440)

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
NCT ID: NCT05308901 (https://classic.clinicaltrials.gov/show/NCT05308901)

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
NCT ID: NCT05827055 (https://classic.clinicaltrials.gov/show/NCT05827055)

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
NCT ID: NCT04971499 (https://classic.clinicaltrials.gov/show/NCT04971499)

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
NCT ID: NCT05130177 (https://classic.clinicaltrials.gov/show/NCT05130177)

Dietary Intervention in Patients With a History of Melanoma
NCT ID: NCT03950635 (https://classic.clinicaltrials.gov/show/NCT03950635)

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
NCT ID: NCT03311308 (https://classic.clinicaltrials.gov/show/NCT03311308)

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
NCT ID: NCT04464759 (https://classic.clinicaltrials.gov/show/NCT04464759)

Use of an Intrauterine Manipulator and Its Correlation With Positive Peritoneal Cytology in Early Stage Endometrial Cancers
NCT ID: NCT04570553 (https://classic.clinicaltrials.gov/show/NCT04570553)

High Dose Omeprazole in Patients With Pancreatic Cancer
NCT ID: NCT04930991 (https://classic.clinicaltrials.gov/show/NCT04930991)

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
NCT ID: NCT05272462 (https://classic.clinicaltrials.gov/show/NCT05272462)

Neoadjuvant Atezolizumab in Cutaneous Melanoma
NCT ID: NCT04020809 (https://classic.clinicaltrials.gov/show/NCT04020809)

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
NCT ID: NCT06216938 (https://classic.clinicaltrials.gov/show/NCT06216938)

Neoadjuvant Combination Immunotherapy for Stage III Melanoma
NCT ID: NCT03842943 (https://classic.clinicaltrials.gov/show/NCT03842943)

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
NCT ID: NCT05089370 (https://classic.clinicaltrials.gov/show/NCT05089370)

Exercise Preconditioning in Ovarian Cancer
NCT ID: NCT05029154 (https://classic.clinicaltrials.gov/show/NCT05029154)

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma
NCT ID: NCT04688658 (https://classic.clinicaltrials.gov/show/NCT04688658)

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma
NCT ID: NCT04513028 (https://classic.clinicaltrials.gov/show/NCT04513028)

PRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma
NCT ID: NCT05546827 (https://classic.clinicaltrials.gov/show/NCT05546827)

Lidocaine Infusion in Pancreatic Cancer
NCT ID: NCT04048278 (https://classic.clinicaltrials.gov/show/NCT04048278)

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
NCT ID: NCT06250335 (https://classic.clinicaltrials.gov/show/NCT06250335)

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
NCT ID: NCT06194929 (https://classic.clinicaltrials.gov/show/NCT06194929)

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT ID: NCT03322995 (https://classic.clinicaltrials.gov/show/NCT03322995)

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
NCT ID: NCT05113368 (https://classic.clinicaltrials.gov/show/NCT05113368)

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
NCT ID: NCT06030622 (https://classic.clinicaltrials.gov/show/NCT06030622)

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
NCT ID: NCT03957551 (https://classic.clinicaltrials.gov/show/NCT03957551)

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT ID: NCT05983276 (https://classic.clinicaltrials.gov/show/NCT05983276)

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT ID: NCT05524935 (https://classic.clinicaltrials.gov/show/NCT05524935)

DeADT - Living Well With Prostate Cancer
NCT ID: NCT06199986 (https://classic.clinicaltrials.gov/show/NCT06199986)

Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
NCT ID: NCT06141031 (https://classic.clinicaltrials.gov/show/NCT06141031)

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
NCT ID: NCT05675059 (https://classic.clinicaltrials.gov/show/NCT05675059)

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
NCT ID: NCT05077280 (https://classic.clinicaltrials.gov/show/NCT05077280)

Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
NCT ID: NCT05836870 (https://classic.clinicaltrials.gov/show/NCT05836870)

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
NCT ID: NCT05415917 (https://classic.clinicaltrials.gov/show/NCT05415917)

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT ID: NCT05764720 (https://classic.clinicaltrials.gov/show/NCT05764720)

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma
NCT ID: NCT06157099 (https://classic.clinicaltrials.gov/show/NCT06157099)

Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
NCT ID: NCT04318717 (https://classic.clinicaltrials.gov/show/NCT04318717)

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer
NCT ID: NCT05483075 (https://classic.clinicaltrials.gov/show/NCT05483075)

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
NCT ID: NCT06121180 (https://classic.clinicaltrials.gov/show/NCT06121180)

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT ID: NCT05170334 (https://classic.clinicaltrials.gov/show/NCT05170334)

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
NCT ID: NCT06036810 (https://classic.clinicaltrials.gov/show/NCT06036810)

Exercise and Nutrition to Improve Pancreatic Cancer Outcomes
NCT ID: NCT03256201 (https://classic.clinicaltrials.gov/show/NCT03256201)

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)
NCT ID: NCT05523700 (https://classic.clinicaltrials.gov/show/NCT05523700)

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
NCT ID: NCT05360732 (https://classic.clinicaltrials.gov/show/NCT05360732)

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
NCT ID: NCT04820179 (https://classic.clinicaltrials.gov/show/NCT04820179)

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
NCT ID: NCT06120972 (https://classic.clinicaltrials.gov/show/NCT06120972)

Time Restricted Eating (TRE) Among Endometrial Cancer Patients
NCT ID: NCT04783467 (https://classic.clinicaltrials.gov/show/NCT04783467)

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
NCT ID: NCT03287271 (https://classic.clinicaltrials.gov/show/NCT03287271)

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT ID: NCT04683653 (https://classic.clinicaltrials.gov/show/NCT04683653)

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT ID: NCT05636111 (https://classic.clinicaltrials.gov/show/NCT05636111)

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
NCT ID: NCT06199466 (https://classic.clinicaltrials.gov/show/NCT06199466)

Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
NCT ID: NCT04473833 (https://classic.clinicaltrials.gov/show/NCT04473833)

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://classic.clinicaltrials.gov/show/NCT05819892)

Anamorelin Study for Advanced Pancreatic Cancer
NCT ID: NCT04844970 (https://classic.clinicaltrials.gov/show/NCT04844970)

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
NCT ID: NCT05634525 (https://classic.clinicaltrials.gov/show/NCT05634525)

Adjuvant Hypofractionated Whole Pelvis Radiation Therapy in Endometrial Cancer
NCT ID: NCT04458402 (https://classic.clinicaltrials.gov/show/NCT04458402)

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT ID: NCT05316129 (https://classic.clinicaltrials.gov/show/NCT05316129)

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05761951 (https://classic.clinicaltrials.gov/show/NCT05761951)

De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
NCT ID: NCT04386993 (https://classic.clinicaltrials.gov/show/NCT04386993)

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
NCT ID: NCT05189457 (https://classic.clinicaltrials.gov/show/NCT05189457)

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
NCT ID: NCT05467670 (https://classic.clinicaltrials.gov/show/NCT05467670)

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
NCT ID: NCT05123807 (https://classic.clinicaltrials.gov/show/NCT05123807)

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT ID: NCT05586360 (https://classic.clinicaltrials.gov/show/NCT05586360)

Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT ID: NCT06295159 (https://classic.clinicaltrials.gov/show/NCT06295159)

Combination Therapy for Recurrent Ovarian Cancer
NCT ID: NCT05610735 (https://classic.clinicaltrials.gov/show/NCT05610735)

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
NCT ID: NCT03385486 (https://classic.clinicaltrials.gov/show/NCT03385486)

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
NCT ID: NCT05866679 (https://classic.clinicaltrials.gov/show/NCT05866679)

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
NCT ID: NCT03232164 (https://classic.clinicaltrials.gov/show/NCT03232164)

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
NCT ID: NCT02672098 (https://classic.clinicaltrials.gov/show/NCT02672098)

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT ID: NCT03832361 (https://classic.clinicaltrials.gov/show/NCT03832361)

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
NCT ID: NCT03467516 (https://classic.clinicaltrials.gov/show/NCT03467516)

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT
NCT ID: NCT05879913 (https://classic.clinicaltrials.gov/show/NCT05879913)

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
NCT ID: NCT05926102 (https://classic.clinicaltrials.gov/show/NCT05926102)

Excision of Lymph Node Trial (EXCILYNT) (Mel69)
NCT ID: NCT05839912 (https://classic.clinicaltrials.gov/show/NCT05839912)

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT ID: NCT05384496 (https://classic.clinicaltrials.gov/show/NCT05384496)

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://classic.clinicaltrials.gov/show/NCT05098210)

CAR T Cell Immunotherapy for Pancreatic Cancer
NCT ID: NCT03323944 (https://classic.clinicaltrials.gov/show/NCT03323944)

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT ID: NCT03769766 (https://classic.clinicaltrials.gov/show/NCT03769766)

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
NCT ID: NCT03674814 (https://classic.clinicaltrials.gov/show/NCT03674814)

Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT ID: NCT05779423 (https://classic.clinicaltrials.gov/show/NCT05779423)

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06059118 (https://classic.clinicaltrials.gov/show/NCT06059118)

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT ID: NCT04346225 (https://classic.clinicaltrials.gov/show/NCT04346225)

Improving Germline Testing in At-Risk Patients With Prostate Cancer
NCT ID: NCT05470036 (https://classic.clinicaltrials.gov/show/NCT05470036)

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
NCT ID: NCT04700332 (https://classic.clinicaltrials.gov/show/NCT04700332)

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
NCT ID: NCT05715216 (https://classic.clinicaltrials.gov/show/NCT05715216)

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
NCT ID: NCT05826470 (https://classic.clinicaltrials.gov/show/NCT05826470)

Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer
NCT ID: NCT04556045 (https://classic.clinicaltrials.gov/show/NCT04556045)

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
NCT ID: NCT04633902 (https://classic.clinicaltrials.gov/show/NCT04633902)

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
NCT ID: NCT06083844 (https://classic.clinicaltrials.gov/show/NCT06083844)

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
NCT ID: NCT03743298 (https://classic.clinicaltrials.gov/show/NCT03743298)

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
NCT ID: NCT03991130 (https://classic.clinicaltrials.gov/show/NCT03991130)

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
NCT ID: NCT05496686 (https://classic.clinicaltrials.gov/show/NCT05496686)

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
NCT ID: NCT05604560 (https://classic.clinicaltrials.gov/show/NCT05604560)

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT ID: NCT05534646 (https://classic.clinicaltrials.gov/show/NCT05534646)

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT ID: NCT04741997 (https://classic.clinicaltrials.gov/show/NCT04741997)

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
NCT ID: NCT04093323 (https://classic.clinicaltrials.gov/show/NCT04093323)

Rectal Spacer for Prostate Cancer Radiation Image Guidance
NCT ID: NCT05650021 (https://classic.clinicaltrials.gov/show/NCT05650021)

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT ID: NCT04562129 (https://classic.clinicaltrials.gov/show/NCT04562129)

Cleveland African American Prostate Cancer Project
NCT ID: NCT05469269 (https://classic.clinicaltrials.gov/show/NCT05469269)

Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT ID: NCT06172283 (https://classic.clinicaltrials.gov/show/NCT06172283)

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: A Pilot Study
NCT ID: NCT05707182 (https://classic.clinicaltrials.gov/show/NCT05707182)

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
NCT ID: NCT05004025 (https://classic.clinicaltrials.gov/show/NCT05004025)

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT ID: NCT05726292 (https://classic.clinicaltrials.gov/show/NCT05726292)

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT ID: NCT03734692 (https://classic.clinicaltrials.gov/show/NCT03734692)

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT ID: NCT04019964 (https://classic.clinicaltrials.gov/show/NCT04019964)

Stereotactic Ablative Radiation Therapy for Prostate Cancer
NCT ID: NCT05668351 (https://classic.clinicaltrials.gov/show/NCT05668351)

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
NCT ID: NCT03955978 (https://classic.clinicaltrials.gov/show/NCT03955978)

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT ID: NCT04665947 (https://classic.clinicaltrials.gov/show/NCT04665947)

UroLift System With SAbR for Prostate Cancer and BPH
NCT ID: NCT05311527 (https://classic.clinicaltrials.gov/show/NCT05311527)

The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
NCT ID: NCT06064149 (https://classic.clinicaltrials.gov/show/NCT06064149)

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer
NCT ID: NCT06111781 (https://classic.clinicaltrials.gov/show/NCT06111781)

Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
NCT ID: NCT04981223 (https://classic.clinicaltrials.gov/show/NCT04981223)

An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
NCT ID: NCT05454488 (https://classic.clinicaltrials.gov/show/NCT05454488)

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
NCT ID: NCT04457089 (https://classic.clinicaltrials.gov/show/NCT04457089)

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
NCT ID: NCT05345444 (https://classic.clinicaltrials.gov/show/NCT05345444)

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT ID: NCT06014255 (https://classic.clinicaltrials.gov/show/NCT06014255)

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT ID: NCT05477823 (https://classic.clinicaltrials.gov/show/NCT05477823)

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
NCT ID: NCT06085729 (https://classic.clinicaltrials.gov/show/NCT06085729)

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer
NCT ID: NCT05790213 (https://classic.clinicaltrials.gov/show/NCT05790213)

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT ID: NCT03223779 (https://classic.clinicaltrials.gov/show/NCT03223779)

AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
NCT ID: NCT05375539 (https://classic.clinicaltrials.gov/show/NCT05375539)

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
NCT ID: NCT05056896 (https://classic.clinicaltrials.gov/show/NCT05056896)

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
NCT ID: NCT06228599 (https://classic.clinicaltrials.gov/show/NCT06228599)

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
NCT ID: NCT06360354 (https://classic.clinicaltrials.gov/show/NCT06360354)

Pilot Study for Black Men With Prostate Cancer: Optimization Of Mental and Heart Health, the BOOM-Heart Study
NCT ID: NCT05099679 (https://classic.clinicaltrials.gov/show/NCT05099679)

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT ID: NCT06171139 (https://classic.clinicaltrials.gov/show/NCT06171139)

Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
NCT ID: NCT04808427 (https://classic.clinicaltrials.gov/show/NCT04808427)

GU-01: Glycyrrhizin in Prostate Cancer
NCT ID: NCT06378346 (https://classic.clinicaltrials.gov/show/NCT06378346)

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
NCT ID: NCT04842890 (https://classic.clinicaltrials.gov/show/NCT04842890)

Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT ID: NCT04588025 (https://classic.clinicaltrials.gov/show/NCT04588025)

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT ID: NCT04116775 (https://classic.clinicaltrials.gov/show/NCT04116775)

Trial of Exercise and Lifestyle in Women With Ovarian Cancer
NCT ID: NCT05761561 (https://classic.clinicaltrials.gov/show/NCT05761561)

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
NCT ID: NCT05942300 (https://classic.clinicaltrials.gov/show/NCT05942300)

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT ID: NCT04552509 (https://classic.clinicaltrials.gov/show/NCT04552509)

Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors
NCT ID: NCT05959395 (https://classic.clinicaltrials.gov/show/NCT05959395)

Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT ID: NCT04349501 (https://classic.clinicaltrials.gov/show/NCT04349501)

Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT ID: NCT04705038 (https://classic.clinicaltrials.gov/show/NCT04705038)

The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
NCT ID: NCT04167969 (https://classic.clinicaltrials.gov/show/NCT04167969)

Cisplatin in Castration Resistant Prostate Cancer
NCT ID: NCT03275857 (https://classic.clinicaltrials.gov/show/NCT03275857)

Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT ID: NCT03971591 (https://classic.clinicaltrials.gov/show/NCT03971591)

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT ID: NCT05751941 (https://classic.clinicaltrials.gov/show/NCT05751941)

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
NCT ID: NCT05679388 (https://classic.clinicaltrials.gov/show/NCT05679388)

MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://classic.clinicaltrials.gov/show/NCT05608694)

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
NCT ID: NCT05068752 (https://classic.clinicaltrials.gov/show/NCT05068752)

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT ID: NCT04989946 (https://classic.clinicaltrials.gov/show/NCT04989946)

FOLFIRINOX + NIS793 in Pancreatic Cancer
NCT ID: NCT05417386 (https://classic.clinicaltrials.gov/show/NCT05417386)

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
NCT ID: NCT03585660 (https://classic.clinicaltrials.gov/show/NCT03585660)

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer
NCT ID: NCT02016248 (https://classic.clinicaltrials.gov/show/NCT02016248)

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT ID: NCT02705196 (https://classic.clinicaltrials.gov/show/NCT02705196)

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
NCT ID: NCT05776524 (https://classic.clinicaltrials.gov/show/NCT05776524)

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer
NCT ID: NCT05245006 (https://classic.clinicaltrials.gov/show/NCT05245006)

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT ID: NCT05628363 (https://classic.clinicaltrials.gov/show/NCT05628363)

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT ID: NCT04402151 (https://classic.clinicaltrials.gov/show/NCT04402151)

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT ID: NCT05710380 (https://classic.clinicaltrials.gov/show/NCT05710380)

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
NCT ID: NCT05141643 (https://classic.clinicaltrials.gov/show/NCT05141643)

Naltrexone and Propranolol Combined With Immunotherapy
NCT ID: NCT05968690 (https://classic.clinicaltrials.gov/show/NCT05968690)

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
NCT ID: NCT04422132 (https://classic.clinicaltrials.gov/show/NCT04422132)

[18F] F-GLN by PET/CT in Breast Cancer
NCT ID: NCT03863457 (https://classic.clinicaltrials.gov/show/NCT03863457)

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
NCT ID: NCT05946824 (https://classic.clinicaltrials.gov/show/NCT05946824)

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
NCT ID: NCT05026983 (https://classic.clinicaltrials.gov/show/NCT05026983)

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT05011188 (https://classic.clinicaltrials.gov/show/NCT05011188)

MRI for Assessing Prostate Cancer Response
NCT ID: NCT01607008 (https://classic.clinicaltrials.gov/show/NCT01607008)

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT ID: NCT05013216 (https://classic.clinicaltrials.gov/show/NCT05013216)

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT ID: NCT02526368 (https://classic.clinicaltrials.gov/show/NCT02526368)

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT ID: NCT03495427 (https://classic.clinicaltrials.gov/show/NCT03495427)

First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT ID: NCT05304962 (https://classic.clinicaltrials.gov/show/NCT05304962)

SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://classic.clinicaltrials.gov/show/NCT04360330)

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT ID: NCT05915442 (https://classic.clinicaltrials.gov/show/NCT05915442)

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
NCT ID: NCT06343077 (https://classic.clinicaltrials.gov/show/NCT06343077)

Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT05156905 (https://classic.clinicaltrials.gov/show/NCT05156905)

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
NCT ID: NCT05722925 (https://classic.clinicaltrials.gov/show/NCT05722925)

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT ID: NCT03932409 (https://classic.clinicaltrials.gov/show/NCT03932409)

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
NCT ID: NCT05851365 (https://classic.clinicaltrials.gov/show/NCT05851365)

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
NCT ID: NCT05396872 (https://classic.clinicaltrials.gov/show/NCT05396872)

A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
NCT ID: NCT05692323 (https://classic.clinicaltrials.gov/show/NCT05692323)

Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
NCT ID: NCT05415696 (https://classic.clinicaltrials.gov/show/NCT05415696)

Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://classic.clinicaltrials.gov/show/NCT02926729)

Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT ID: NCT03861975 (https://classic.clinicaltrials.gov/show/NCT03861975)

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT ID: NCT04692675 (https://classic.clinicaltrials.gov/show/NCT04692675)

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
NCT ID: NCT05497778 (https://classic.clinicaltrials.gov/show/NCT05497778)

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT ID: NCT05628883 (https://classic.clinicaltrials.gov/show/NCT05628883)

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT ID: NCT05504707 (https://classic.clinicaltrials.gov/show/NCT05504707)

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT ID: NCT04670068 (https://classic.clinicaltrials.gov/show/NCT04670068)

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
NCT ID: NCT05077098 (https://classic.clinicaltrials.gov/show/NCT05077098)

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT ID: NCT03652428 (https://classic.clinicaltrials.gov/show/NCT03652428)

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
NCT ID: NCT05913388 (https://classic.clinicaltrials.gov/show/NCT05913388)

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix
NCT ID: NCT05558956 (https://classic.clinicaltrials.gov/show/NCT05558956)

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
NCT ID: NCT04502602 (https://classic.clinicaltrials.gov/show/NCT04502602)

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
NCT ID: NCT06029998 (https://classic.clinicaltrials.gov/show/NCT06029998)

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT ID: NCT03765983 (https://classic.clinicaltrials.gov/show/NCT03765983)

Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT ID: NCT02040610 (https://classic.clinicaltrials.gov/show/NCT02040610)

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT ID: NCT05803941 (https://classic.clinicaltrials.gov/show/NCT05803941)

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT ID: NCT05462496 (https://classic.clinicaltrials.gov/show/NCT05462496)

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT ID: NCT05542407 (https://classic.clinicaltrials.gov/show/NCT05542407)

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT ID: NCT05074290 (https://classic.clinicaltrials.gov/show/NCT05074290)

BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
NCT ID: NCT03553602 (https://classic.clinicaltrials.gov/show/NCT03553602)

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
NCT ID: NCT05086250 (https://classic.clinicaltrials.gov/show/NCT05086250)

Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
NCT ID: NCT04651452 (https://classic.clinicaltrials.gov/show/NCT04651452)

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
NCT ID: NCT04158635 (https://classic.clinicaltrials.gov/show/NCT04158635)

Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
NCT ID: NCT05174286 (https://classic.clinicaltrials.gov/show/NCT05174286)

Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT ID: NCT05327452 (https://classic.clinicaltrials.gov/show/NCT05327452)

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05613894 (https://classic.clinicaltrials.gov/show/NCT05613894)

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT ID: NCT05327465 (https://classic.clinicaltrials.gov/show/NCT05327465)

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04754191 (https://classic.clinicaltrials.gov/show/NCT04754191)

BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT ID: NCT05051631 (https://classic.clinicaltrials.gov/show/NCT05051631)

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT04109729 (https://classic.clinicaltrials.gov/show/NCT04109729)

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT ID: NCT03543969 (https://classic.clinicaltrials.gov/show/NCT03543969)

EXERT-BCN: An Exercise and Nutrition Regimen to Designed to Improve Body Composition After Treatment for Breast Cancer
NCT ID: NCT05978960 (https://classic.clinicaltrials.gov/show/NCT05978960)

Pilot Window of Opportunity Trial (POET)
NCT ID: NCT06129604 (https://classic.clinicaltrials.gov/show/NCT06129604)

Acupressure for Fatigue in Ovarian Cancer Survivors
NCT ID: NCT03763838 (https://classic.clinicaltrials.gov/show/NCT03763838)

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
NCT ID: NCT05085548 (https://classic.clinicaltrials.gov/show/NCT05085548)

Radium-223 in Biochemically Recurrent Prostate Cancer
NCT ID: NCT04206319 (https://classic.clinicaltrials.gov/show/NCT04206319)

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
NCT ID: NCT05806814 (https://classic.clinicaltrials.gov/show/NCT05806814)

Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men
NCT ID: NCT05331638 (https://classic.clinicaltrials.gov/show/NCT05331638)

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
NCT ID: NCT05424783 (https://classic.clinicaltrials.gov/show/NCT05424783)

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05743621 (https://classic.clinicaltrials.gov/show/NCT05743621)

Exercise Timing in Breast Cancer Patients
NCT ID: NCT05821244 (https://classic.clinicaltrials.gov/show/NCT05821244)

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
NCT ID: NCT04132505 (https://classic.clinicaltrials.gov/show/NCT04132505)

Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors
NCT ID: NCT05931874 (https://classic.clinicaltrials.gov/show/NCT05931874)

FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
NCT ID: NCT03212170 (https://classic.clinicaltrials.gov/show/NCT03212170)

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT ID: NCT05804318 (https://classic.clinicaltrials.gov/show/NCT05804318)

Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging
NCT ID: NCT03761706 (https://classic.clinicaltrials.gov/show/NCT03761706)

Diffusion Basis Spectrum Imaging of the Prostate
NCT ID: NCT04420702 (https://classic.clinicaltrials.gov/show/NCT04420702)

Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy
NCT ID: NCT05324098 (https://classic.clinicaltrials.gov/show/NCT05324098)

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT ID: NCT05968157 (https://classic.clinicaltrials.gov/show/NCT05968157)

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT ID: NCT05263492 (https://classic.clinicaltrials.gov/show/NCT05263492)

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
NCT ID: NCT06229392 (https://classic.clinicaltrials.gov/show/NCT06229392)

Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://classic.clinicaltrials.gov/show/NCT05505643)

Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT ID: NCT04270149 (https://classic.clinicaltrials.gov/show/NCT04270149)

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
NCT ID: NCT05501548 (https://classic.clinicaltrials.gov/show/NCT05501548)

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT ID: NCT06328738 (https://classic.clinicaltrials.gov/show/NCT06328738)

A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men
NCT ID: NCT06052202 (https://classic.clinicaltrials.gov/show/NCT06052202)

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://classic.clinicaltrials.gov/show/NCT05378464)

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
NCT ID: NCT04728633 (https://classic.clinicaltrials.gov/show/NCT04728633)

Strength After Breast Cancer
NCT ID: NCT06052488 (https://classic.clinicaltrials.gov/show/NCT06052488)

Shared Decision-making and Colorectal Cancer Screening
NCT ID: NCT04748380 (https://classic.clinicaltrials.gov/show/NCT04748380)

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT ID: NCT04465500 (https://classic.clinicaltrials.gov/show/NCT04465500)

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
NCT ID: NCT03668431 (https://classic.clinicaltrials.gov/show/NCT03668431)

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT ID: NCT03742245 (https://classic.clinicaltrials.gov/show/NCT03742245)

High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT ID: NCT06212583 (https://classic.clinicaltrials.gov/show/NCT06212583)

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
NCT ID: NCT05999812 (https://classic.clinicaltrials.gov/show/NCT05999812)

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
NCT ID: NCT05810025 (https://classic.clinicaltrials.gov/show/NCT05810025)

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://classic.clinicaltrials.gov/show/NCT05950945)

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
NCT ID: NCT02207465 (https://classic.clinicaltrials.gov/show/NCT02207465)

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
NCT ID: NCT06151847 (https://classic.clinicaltrials.gov/show/NCT06151847)

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://classic.clinicaltrials.gov/show/NCT03694756)

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
NCT ID: NCT05343013 (https://classic.clinicaltrials.gov/show/NCT05343013)

Promoting CT Engagement for Pancreatic Cancer With App
NCT ID: NCT06252545 (https://classic.clinicaltrials.gov/show/NCT06252545)

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT05723107 (https://classic.clinicaltrials.gov/show/NCT05723107)

Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People
NCT ID: NCT04336397 (https://classic.clinicaltrials.gov/show/NCT04336397)

Promoting Resilience in Women With Breast Cancer
NCT ID: NCT06133348 (https://classic.clinicaltrials.gov/show/NCT06133348)

HIIT Following Breast Cancer Chemotherapy
NCT ID: NCT05913713 (https://classic.clinicaltrials.gov/show/NCT05913713)

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
NCT ID: NCT03321188 (https://classic.clinicaltrials.gov/show/NCT03321188)

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT ID: NCT06001268 (https://classic.clinicaltrials.gov/show/NCT06001268)

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
NCT ID: NCT06085664 (https://classic.clinicaltrials.gov/show/NCT06085664)

Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention
NCT ID: NCT04192071 (https://classic.clinicaltrials.gov/show/NCT04192071)

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT ID: NCT05361798 (https://classic.clinicaltrials.gov/show/NCT05361798)

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://classic.clinicaltrials.gov/show/NCT04768426)

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT ID: NCT04039230 (https://classic.clinicaltrials.gov/show/NCT04039230)

Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer
NCT ID: NCT05092763 (https://classic.clinicaltrials.gov/show/NCT05092763)

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://classic.clinicaltrials.gov/show/NCT04997096)

Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
NCT ID: NCT05607095 (https://classic.clinicaltrials.gov/show/NCT05607095)

Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://classic.clinicaltrials.gov/show/NCT05464667)

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://classic.clinicaltrials.gov/show/NCT04965064)

3D Printed Breast Models in the Surgical Management of Breast Cancer
NCT ID: NCT05755984 (https://classic.clinicaltrials.gov/show/NCT05755984)

Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function
NCT ID: NCT06081127 (https://classic.clinicaltrials.gov/show/NCT06081127)

Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
NCT ID: NCT06090916 (https://classic.clinicaltrials.gov/show/NCT06090916)

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
NCT ID: NCT03496805 (https://classic.clinicaltrials.gov/show/NCT03496805)

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT ID: NCT05334732 (https://classic.clinicaltrials.gov/show/NCT05334732)

Adherence Intervention in Patients With Metastatic Breast Cancer
NCT ID: NCT06121453 (https://classic.clinicaltrials.gov/show/NCT06121453)

COAST Therapy in Advanced Solid Tumors and Prostate Cancer
NCT ID: NCT05036226 (https://classic.clinicaltrials.gov/show/NCT05036226)

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://classic.clinicaltrials.gov/show/NCT05766891)

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://classic.clinicaltrials.gov/show/NCT05625659)

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT ID: NCT05483283 (https://classic.clinicaltrials.gov/show/NCT05483283)

Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
NCT ID: NCT06096870 (https://classic.clinicaltrials.gov/show/NCT06096870)

CAR T Cells in Mesothelin-Expressing Breast Cancer
NCT ID: NCT05623488 (https://classic.clinicaltrials.gov/show/NCT05623488)

Assessment of Research Digest Impact for Minority With Prostate Cancer, MiCAP Phase III Study
NCT ID: NCT05895279 (https://classic.clinicaltrials.gov/show/NCT05895279)

Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials
NCT ID: NCT06361056 (https://classic.clinicaltrials.gov/show/NCT06361056)

FES BPET-DBT in Newly Diagnosed Breast Cancer
NCT ID: NCT05659797 (https://classic.clinicaltrials.gov/show/NCT05659797)

Exercise Post-Diagnosis of Breast Cancer
NCT ID: NCT04013568 (https://classic.clinicaltrials.gov/show/NCT04013568)

All-extremity Exercise During Breast Cancer Chemotherapy
NCT ID: NCT04914663 (https://classic.clinicaltrials.gov/show/NCT04914663)

Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer
NCT ID: NCT05609435 (https://classic.clinicaltrials.gov/show/NCT05609435)

Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
NCT ID: NCT05984888 (https://classic.clinicaltrials.gov/show/NCT05984888)

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
NCT ID: NCT03933670 (https://classic.clinicaltrials.gov/show/NCT03933670)

Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy
NCT ID: NCT05704842 (https://classic.clinicaltrials.gov/show/NCT05704842)

Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT ID: NCT05665660 (https://classic.clinicaltrials.gov/show/NCT05665660)

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
NCT ID: NCT05130840 (https://classic.clinicaltrials.gov/show/NCT05130840)

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT ID: NCT03025035 (https://classic.clinicaltrials.gov/show/NCT03025035)

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
NCT ID: NCT05854498 (https://classic.clinicaltrials.gov/show/NCT05854498)

Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors
NCT ID: NCT05615753 (https://classic.clinicaltrials.gov/show/NCT05615753)

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NCT ID: NCT06127979 (https://classic.clinicaltrials.gov/show/NCT06127979)

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT ID: NCT04756765 (https://classic.clinicaltrials.gov/show/NCT04756765)

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT ID: NCT05183126 (https://classic.clinicaltrials.gov/show/NCT05183126)

Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors
NCT ID: NCT05417451 (https://classic.clinicaltrials.gov/show/NCT05417451)

Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients With Prostate Cancer
NCT ID: NCT06016504 (https://classic.clinicaltrials.gov/show/NCT06016504)

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT ID: NCT05675579 (https://classic.clinicaltrials.gov/show/NCT05675579)

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://classic.clinicaltrials.gov/show/NCT05856773)

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT ID: NCT03272334 (https://classic.clinicaltrials.gov/show/NCT03272334)

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
NCT ID: NCT04141995 (https://classic.clinicaltrials.gov/show/NCT04141995)

Couples' QOL in Metastatic Breast Cancer
NCT ID: NCT05636943 (https://classic.clinicaltrials.gov/show/NCT05636943)

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT ID: NCT05633979 (https://classic.clinicaltrials.gov/show/NCT05633979)

Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
NCT ID: NCT05838417 (https://classic.clinicaltrials.gov/show/NCT05838417)

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT ID: NCT06085742 (https://classic.clinicaltrials.gov/show/NCT06085742)

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
NCT ID: NCT04493034 (https://classic.clinicaltrials.gov/show/NCT04493034)

A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors
NCT ID: NCT04594473 (https://classic.clinicaltrials.gov/show/NCT04594473)

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT ID: NCT05384535 (https://classic.clinicaltrials.gov/show/NCT05384535)

Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
NCT ID: NCT06200259 (https://classic.clinicaltrials.gov/show/NCT06200259)

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT06149481 (https://classic.clinicaltrials.gov/show/NCT06149481)

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT ID: NCT04633252 (https://classic.clinicaltrials.gov/show/NCT04633252)

Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
NCT ID: NCT05957042 (https://classic.clinicaltrials.gov/show/NCT05957042)

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT ID: NCT03400215 (https://classic.clinicaltrials.gov/show/NCT03400215)

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
NCT ID: NCT05754580 (https://classic.clinicaltrials.gov/show/NCT05754580)

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT ID: NCT03820141 (https://classic.clinicaltrials.gov/show/NCT03820141)

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT ID: NCT04495257 (https://classic.clinicaltrials.gov/show/NCT04495257)

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
NCT ID: NCT04858009 (https://classic.clinicaltrials.gov/show/NCT04858009)

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT ID: NCT05042687 (https://classic.clinicaltrials.gov/show/NCT05042687)

CyberKnife Dose Escalation Prostate Cancer Trial
NCT ID: NCT03822494 (https://classic.clinicaltrials.gov/show/NCT03822494)

A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
NCT ID: NCT04040569 (https://classic.clinicaltrials.gov/show/NCT04040569)

Time Restricted Eating During Chemotherapy for Breast Cancer
NCT ID: NCT05259410 (https://classic.clinicaltrials.gov/show/NCT05259410)

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
NCT ID: NCT05243641 (https://classic.clinicaltrials.gov/show/NCT05243641)

Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer
NCT ID: NCT04354675 (https://classic.clinicaltrials.gov/show/NCT04354675)

Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca
NCT ID: NCT06250751 (https://classic.clinicaltrials.gov/show/NCT06250751)

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT ID: NCT05933395 (https://classic.clinicaltrials.gov/show/NCT05933395)

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
NCT ID: NCT05985954 (https://classic.clinicaltrials.gov/show/NCT05985954)

Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study
NCT ID: NCT05067777 (https://classic.clinicaltrials.gov/show/NCT05067777)

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
NCT ID: NCT05160597 (https://classic.clinicaltrials.gov/show/NCT05160597)

Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
NCT ID: NCT03712813 (https://classic.clinicaltrials.gov/show/NCT03712813)

Phase 1 Dose Escalation of ArtemiCoffee
NCT ID: NCT04805333 (https://classic.clinicaltrials.gov/show/NCT04805333)

Focused Ultrasound and Gemcitabine in Breast Cancer
NCT ID: NCT04796220 (https://classic.clinicaltrials.gov/show/NCT04796220)

Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT ID: NCT02958774 (https://classic.clinicaltrials.gov/show/NCT02958774)

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://classic.clinicaltrials.gov/show/NCT05528133)

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
NCT ID: NCT03802851 (https://classic.clinicaltrials.gov/show/NCT03802851)

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
NCT ID: NCT06027268 (https://classic.clinicaltrials.gov/show/NCT06027268)

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT ID: NCT03699995 (https://classic.clinicaltrials.gov/show/NCT03699995)

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
NCT ID: NCT05219500 (https://classic.clinicaltrials.gov/show/NCT05219500)

Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
NCT ID: NCT02706561 (https://classic.clinicaltrials.gov/show/NCT02706561)

Magnetic Resonance Imaging of Breast Cancer
NCT ID: NCT01035112 (https://classic.clinicaltrials.gov/show/NCT01035112)

Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://classic.clinicaltrials.gov/show/NCT04990921)

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
NCT ID: NCT03824145 (https://classic.clinicaltrials.gov/show/NCT03824145)

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
NCT ID: NCT05716516 (https://classic.clinicaltrials.gov/show/NCT05716516)

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
NCT ID: NCT05045066 (https://classic.clinicaltrials.gov/show/NCT05045066)

The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer
NCT ID: NCT03808077 (https://classic.clinicaltrials.gov/show/NCT03808077)

Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT ID: NCT04243616 (https://classic.clinicaltrials.gov/show/NCT04243616)

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT05445609 (https://classic.clinicaltrials.gov/show/NCT05445609)

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
NCT ID: NCT03436745 (https://classic.clinicaltrials.gov/show/NCT03436745)

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://classic.clinicaltrials.gov/show/NCT05305924)

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NCT ID: NCT05959291 (https://classic.clinicaltrials.gov/show/NCT05959291)

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
NCT ID: NCT04857502 (https://classic.clinicaltrials.gov/show/NCT04857502)

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
NCT ID: NCT06173362 (https://classic.clinicaltrials.gov/show/NCT06173362)

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT ID: NCT04523857 (https://classic.clinicaltrials.gov/show/NCT04523857)

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://classic.clinicaltrials.gov/show/NCT04891068)

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT ID: NCT02807597 (https://classic.clinicaltrials.gov/show/NCT02807597)

Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia
NCT ID: NCT04427527 (https://classic.clinicaltrials.gov/show/NCT04427527)

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://classic.clinicaltrials.gov/show/NCT04020575)

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT ID: NCT03492671 (https://classic.clinicaltrials.gov/show/NCT03492671)

HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
NCT ID: NCT01913106 (https://classic.clinicaltrials.gov/show/NCT01913106)

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
NCT ID: NCT05169957 (https://classic.clinicaltrials.gov/show/NCT05169957)

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
NCT ID: NCT05155033 (https://classic.clinicaltrials.gov/show/NCT05155033)

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
NCT ID: NCT05588453 (https://classic.clinicaltrials.gov/show/NCT05588453)

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://classic.clinicaltrials.gov/show/NCT05748834)

An mHealth Symptom Management Intervention for Colorectal Cancer Patients (mCOPE)
NCT ID: NCT04763174 (https://classic.clinicaltrials.gov/show/NCT04763174)

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
NCT ID: NCT04709276 (https://classic.clinicaltrials.gov/show/NCT04709276)

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT ID: NCT04332588 (https://classic.clinicaltrials.gov/show/NCT04332588)

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT ID: NCT02732171 (https://classic.clinicaltrials.gov/show/NCT02732171)

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
NCT ID: NCT04968964 (https://classic.clinicaltrials.gov/show/NCT04968964)

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
NCT ID: NCT05764395 (https://classic.clinicaltrials.gov/show/NCT05764395)

Effect of Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer
NCT ID: NCT06019988 (https://classic.clinicaltrials.gov/show/NCT06019988)

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
NCT ID: NCT06257758 (https://classic.clinicaltrials.gov/show/NCT06257758)

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT ID: NCT04748042 (https://classic.clinicaltrials.gov/show/NCT04748042)

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
NCT ID: NCT05176756 (https://classic.clinicaltrials.gov/show/NCT05176756)

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
NCT ID: NCT04853043 (https://classic.clinicaltrials.gov/show/NCT04853043)

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://classic.clinicaltrials.gov/show/NCT04427293)

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
NCT ID: NCT05081193 (https://classic.clinicaltrials.gov/show/NCT05081193)

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
NCT ID: NCT05187832 (https://classic.clinicaltrials.gov/show/NCT05187832)

Functional Precision Oncology for Metastatic Breast Cancer
NCT ID: NCT04450706 (https://classic.clinicaltrials.gov/show/NCT04450706)

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://classic.clinicaltrials.gov/show/NCT05351424)

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
NCT ID: NCT05071937 (https://classic.clinicaltrials.gov/show/NCT05071937)

7T MRI Scan for the Early Detection of Melanoma Brain Metastases
NCT ID: NCT04941430 (https://classic.clinicaltrials.gov/show/NCT04941430)

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
NCT ID: NCT04273555 (https://classic.clinicaltrials.gov/show/NCT04273555)

Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
NCT ID: NCT04364672 (https://classic.clinicaltrials.gov/show/NCT04364672)

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT06305598 (https://classic.clinicaltrials.gov/show/NCT06305598)

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT ID: NCT05766371 (https://classic.clinicaltrials.gov/show/NCT05766371)

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT05479578 (https://classic.clinicaltrials.gov/show/NCT05479578)

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
NCT ID: NCT04090528 (https://classic.clinicaltrials.gov/show/NCT04090528)

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://classic.clinicaltrials.gov/show/NCT05130801)

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
NCT ID: NCT06060587 (https://classic.clinicaltrials.gov/show/NCT06060587)

ArtemiCoffee in Patients With Rising PSA
NCT ID: NCT05478239 (https://classic.clinicaltrials.gov/show/NCT05478239)

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://classic.clinicaltrials.gov/show/NCT06239467)

Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT ID: NCT04568616 (https://classic.clinicaltrials.gov/show/NCT04568616)

Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT ID: NCT04542135 (https://classic.clinicaltrials.gov/show/NCT04542135)

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05805371 (https://classic.clinicaltrials.gov/show/NCT05805371)

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
NCT ID: NCT02935205 (https://classic.clinicaltrials.gov/show/NCT02935205)

Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer
NCT ID: NCT05318469 (https://classic.clinicaltrials.gov/show/NCT05318469)

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
NCT ID: NCT04698564 (https://classic.clinicaltrials.gov/show/NCT04698564)

Study of Stereotactic Radiotherapy for Breast Cancer
NCT ID: NCT03043794 (https://classic.clinicaltrials.gov/show/NCT03043794)

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
NCT ID: NCT05010200 (https://classic.clinicaltrials.gov/show/NCT05010200)

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://classic.clinicaltrials.gov/show/NCT06026657)

High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
NCT ID: NCT05838716 (https://classic.clinicaltrials.gov/show/NCT05838716)

Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
NCT ID: NCT05765214 (https://classic.clinicaltrials.gov/show/NCT05765214)

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
NCT ID: NCT03861676 (https://classic.clinicaltrials.gov/show/NCT03861676)

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT ID: NCT04573231 (https://classic.clinicaltrials.gov/show/NCT04573231)

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
NCT ID: NCT05530655 (https://classic.clinicaltrials.gov/show/NCT05530655)

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT ID: NCT03821246 (https://classic.clinicaltrials.gov/show/NCT03821246)

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
NCT ID: NCT05225363 (https://classic.clinicaltrials.gov/show/NCT05225363)

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT ID: NCT04725903 (https://classic.clinicaltrials.gov/show/NCT04725903)

mHealth for Breast Cancer Survivors With Insomnia
NCT ID: NCT05233800 (https://classic.clinicaltrials.gov/show/NCT05233800)

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT ID: NCT03711890 (https://classic.clinicaltrials.gov/show/NCT03711890)

Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer
NCT ID: NCT05101564 (https://classic.clinicaltrials.gov/show/NCT05101564)

Breast Cancer Survivor Educational Intervention
NCT ID: NCT05700396 (https://classic.clinicaltrials.gov/show/NCT05700396)

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
NCT ID: NCT06100874 (https://classic.clinicaltrials.gov/show/NCT06100874)

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
NCT ID: NCT04337580 (https://classic.clinicaltrials.gov/show/NCT04337580)

Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
NCT ID: NCT04965688 (https://classic.clinicaltrials.gov/show/NCT04965688)

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
NCT ID: NCT06228768 (https://classic.clinicaltrials.gov/show/NCT06228768)

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03801369 (https://classic.clinicaltrials.gov/show/NCT03801369)

Genetic Testing in African Americans
NCT ID: NCT05591131 (https://classic.clinicaltrials.gov/show/NCT05591131)

Two Fraction Prostate SBRT With DIL SIB
NCT ID: NCT05864196 (https://classic.clinicaltrials.gov/show/NCT05864196)

DCE MRI in Patients With Pancreatic Cancer
NCT ID: NCT02070705 (https://classic.clinicaltrials.gov/show/NCT02070705)

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
NCT ID: NCT05077137 (https://classic.clinicaltrials.gov/show/NCT05077137)

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
NCT ID: NCT05806138 (https://classic.clinicaltrials.gov/show/NCT05806138)

Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
NCT ID: NCT05374915 (https://classic.clinicaltrials.gov/show/NCT05374915)

Patient Recall of Cancer Screening and Diagnosis
NCT ID: NCT05014295 (https://classic.clinicaltrials.gov/show/NCT05014295)

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NCT ID: NCT05984602 (https://classic.clinicaltrials.gov/show/NCT05984602)

PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
NCT ID: NCT06132087 (https://classic.clinicaltrials.gov/show/NCT06132087)

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT ID: NCT05139368 (https://classic.clinicaltrials.gov/show/NCT05139368)

The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
NCT ID: NCT05676255 (https://classic.clinicaltrials.gov/show/NCT05676255)

Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT ID: NCT05472792 (https://classic.clinicaltrials.gov/show/NCT05472792)

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT ID: NCT06136884 (https://classic.clinicaltrials.gov/show/NCT06136884)

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://classic.clinicaltrials.gov/show/NCT05746897)

Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
NCT ID: NCT04753359 (https://classic.clinicaltrials.gov/show/NCT04753359)

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
NCT ID: NCT06129422 (https://classic.clinicaltrials.gov/show/NCT06129422)

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
NCT ID: NCT05722327 (https://classic.clinicaltrials.gov/show/NCT05722327)

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
NCT ID: NCT05852041 (https://classic.clinicaltrials.gov/show/NCT05852041)

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
NCT ID: NCT04539808 (https://classic.clinicaltrials.gov/show/NCT04539808)

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study
NCT ID: NCT04645680 (https://classic.clinicaltrials.gov/show/NCT04645680)

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
NCT ID: NCT06244004 (https://classic.clinicaltrials.gov/show/NCT06244004)

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT ID: NCT03835819 (https://classic.clinicaltrials.gov/show/NCT03835819)

Telemonitoring Hypertension and Breast Cancer
NCT ID: NCT05574686 (https://classic.clinicaltrials.gov/show/NCT05574686)

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
NCT ID: NCT03889795 (https://classic.clinicaltrials.gov/show/NCT03889795)

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
NCT ID: NCT05576896 (https://classic.clinicaltrials.gov/show/NCT05576896)

Cardiac Rehabilitation to Improve Breast Cancer Outcomes
NCT ID: NCT05867667 (https://classic.clinicaltrials.gov/show/NCT05867667)

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
NCT ID: NCT04594187 (https://classic.clinicaltrials.gov/show/NCT04594187)

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT ID: NCT04458532 (https://classic.clinicaltrials.gov/show/NCT04458532)

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
NCT ID: NCT06274034 (https://classic.clinicaltrials.gov/show/NCT06274034)

Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study
NCT ID: NCT06323291 (https://classic.clinicaltrials.gov/show/NCT06323291)

Prospective Breast Cancer Biospecimen Collection
NCT ID: NCT04074720 (https://classic.clinicaltrials.gov/show/NCT04074720)

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT ID: NCT05616650 (https://classic.clinicaltrials.gov/show/NCT05616650)

Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT ID: NCT05013255 (https://classic.clinicaltrials.gov/show/NCT05013255)

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT ID: NCT05553522 (https://classic.clinicaltrials.gov/show/NCT05553522)

Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
NCT ID: NCT03757689 (https://classic.clinicaltrials.gov/show/NCT03757689)

ICG and SLN Mapping
NCT ID: NCT05859971 (https://classic.clinicaltrials.gov/show/NCT05859971)

A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
NCT ID: NCT05812924 (https://classic.clinicaltrials.gov/show/NCT05812924)

Acute Exercise Intervention in Breast Cancer Survivors
NCT ID: NCT03779867 (https://classic.clinicaltrials.gov/show/NCT03779867)

Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer
NCT ID: NCT06219434 (https://classic.clinicaltrials.gov/show/NCT06219434)

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
NCT ID: NCT05787834 (https://classic.clinicaltrials.gov/show/NCT05787834)

Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer
NCT ID: NCT05132296 (https://classic.clinicaltrials.gov/show/NCT05132296)

Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups
NCT ID: NCT06090643 (https://classic.clinicaltrials.gov/show/NCT06090643)

Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
NCT ID: NCT04267796 (https://classic.clinicaltrials.gov/show/NCT04267796)

Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer
NCT ID: NCT04378751 (https://classic.clinicaltrials.gov/show/NCT04378751)

Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities
NCT ID: NCT05447923 (https://classic.clinicaltrials.gov/show/NCT05447923)

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT ID: NCT06300463 (https://classic.clinicaltrials.gov/show/NCT06300463)

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
NCT ID: NCT04697576 (https://classic.clinicaltrials.gov/show/NCT04697576)

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
NCT ID: NCT04469764 (https://classic.clinicaltrials.gov/show/NCT04469764)

A Web-Based Dyadic Intervention for Colorectal Cancer
NCT ID: NCT05663203 (https://classic.clinicaltrials.gov/show/NCT05663203)

Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT ID: NCT04721886 (https://classic.clinicaltrials.gov/show/NCT04721886)

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
NCT ID: NCT04913064 (https://classic.clinicaltrials.gov/show/NCT04913064)

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
NCT ID: NCT05325151 (https://classic.clinicaltrials.gov/show/NCT05325151)

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://classic.clinicaltrials.gov/show/NCT05325632)

Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment
NCT ID: NCT05928325 (https://classic.clinicaltrials.gov/show/NCT05928325)

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
NCT ID: NCT06115486 (https://classic.clinicaltrials.gov/show/NCT06115486)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT ID: NCT04251416 (https://classic.clinicaltrials.gov/show/NCT04251416)

A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT ID: NCT03945721 (https://classic.clinicaltrials.gov/show/NCT03945721)

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer
NCT ID: NCT06369610 (https://classic.clinicaltrials.gov/show/NCT06369610)

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT ID: NCT06011772 (https://classic.clinicaltrials.gov/show/NCT06011772)

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
NCT ID: NCT05036109 (https://classic.clinicaltrials.gov/show/NCT05036109)

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT ID: NCT04098081 (https://classic.clinicaltrials.gov/show/NCT04098081)

Taking AIM at Breast Cancer
NCT ID: NCT04720209 (https://classic.clinicaltrials.gov/show/NCT04720209)

Pembro With Radiation With or Without Olaparib
NCT ID: NCT05568550 (https://classic.clinicaltrials.gov/show/NCT05568550)

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
NCT ID: NCT04375527 (https://classic.clinicaltrials.gov/show/NCT04375527)

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT ID: NCT03646617 (https://classic.clinicaltrials.gov/show/NCT03646617)

A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT ID: NCT05408260 (https://classic.clinicaltrials.gov/show/NCT05408260)

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT ID: NCT04896073 (https://classic.clinicaltrials.gov/show/NCT04896073)

Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://classic.clinicaltrials.gov/show/NCT04824027)

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
NCT ID: NCT04506567 (https://classic.clinicaltrials.gov/show/NCT04506567)

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT ID: NCT05200442 (https://classic.clinicaltrials.gov/show/NCT05200442)

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
NCT ID: NCT06100705 (https://classic.clinicaltrials.gov/show/NCT06100705)

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
NCT ID: NCT05830058 (https://classic.clinicaltrials.gov/show/NCT05830058)

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://classic.clinicaltrials.gov/show/NCT05603910)

Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer
NCT ID: NCT03675893 (https://classic.clinicaltrials.gov/show/NCT03675893)

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT ID: NCT05391126 (https://classic.clinicaltrials.gov/show/NCT05391126)

Video Education With Result Dependent dIsclosure
NCT ID: NCT05225428 (https://classic.clinicaltrials.gov/show/NCT05225428)

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
NCT ID: NCT06193486 (https://classic.clinicaltrials.gov/show/NCT06193486)

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT ID: NCT02600949 (https://classic.clinicaltrials.gov/show/NCT02600949)

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT ID: NCT03977233 (https://classic.clinicaltrials.gov/show/NCT03977233)

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
NCT ID: NCT05841706 (https://classic.clinicaltrials.gov/show/NCT05841706)

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
NCT ID: NCT05141149 (https://classic.clinicaltrials.gov/show/NCT05141149)

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
NCT ID: NCT04777071 (https://classic.clinicaltrials.gov/show/NCT04777071)

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
NCT ID: NCT06072807 (https://classic.clinicaltrials.gov/show/NCT06072807)

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT ID: NCT04674306 (https://classic.clinicaltrials.gov/show/NCT04674306)

Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
NCT ID: NCT05882253 (https://classic.clinicaltrials.gov/show/NCT05882253)

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT ID: NCT03439735 (https://classic.clinicaltrials.gov/show/NCT03439735)

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
NCT ID: NCT06028932 (https://classic.clinicaltrials.gov/show/NCT06028932)

Living WELL: A Web-Based Program for Ovarian Cancer Survivors
NCT ID: NCT04533763 (https://classic.clinicaltrials.gov/show/NCT04533763)

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT ID: NCT04866810 (https://classic.clinicaltrials.gov/show/NCT04866810)

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT ID: NCT06139107 (https://classic.clinicaltrials.gov/show/NCT06139107)

Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
NCT ID: NCT06178354 (https://classic.clinicaltrials.gov/show/NCT06178354)

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
NCT ID: NCT02681549 (https://classic.clinicaltrials.gov/show/NCT02681549)

Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
NCT ID: NCT02600156 (https://classic.clinicaltrials.gov/show/NCT02600156)

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://classic.clinicaltrials.gov/show/NCT05288777)

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
NCT ID: NCT05733351 (https://classic.clinicaltrials.gov/show/NCT05733351)

ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT ID: NCT06015659 (https://classic.clinicaltrials.gov/show/NCT06015659)

TmPSMA-02 in mCRPC
NCT ID: NCT06046040 (https://classic.clinicaltrials.gov/show/NCT06046040)

Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance
NCT ID: NCT05764330 (https://classic.clinicaltrials.gov/show/NCT05764330)

Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://classic.clinicaltrials.gov/show/NCT06006806)

Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT ID: NCT06260332 (https://classic.clinicaltrials.gov/show/NCT06260332)

Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT ID: NCT05918263 (https://classic.clinicaltrials.gov/show/NCT05918263)

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT ID: NCT05649072 (https://classic.clinicaltrials.gov/show/NCT05649072)

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://classic.clinicaltrials.gov/show/NCT05524584)

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT ID: NCT04486755 (https://classic.clinicaltrials.gov/show/NCT04486755)

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
NCT ID: NCT05497531 (https://classic.clinicaltrials.gov/show/NCT05497531)

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT ID: NCT05150652 (https://classic.clinicaltrials.gov/show/NCT05150652)

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT ID: NCT05568680 (https://classic.clinicaltrials.gov/show/NCT05568680)

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT ID: NCT05826964 (https://classic.clinicaltrials.gov/show/NCT05826964)

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
NCT ID: NCT05168618 (https://classic.clinicaltrials.gov/show/NCT05168618)

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
NCT ID: NCT02884648 (https://classic.clinicaltrials.gov/show/NCT02884648)

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
NCT ID: NCT04984343 (https://classic.clinicaltrials.gov/show/NCT04984343)

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT ID: NCT03526432 (https://classic.clinicaltrials.gov/show/NCT03526432)

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT ID: NCT03729115 (https://classic.clinicaltrials.gov/show/NCT03729115)

Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
NCT ID: NCT02334579 (https://classic.clinicaltrials.gov/show/NCT02334579)

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://classic.clinicaltrials.gov/show/NCT05595499)

Scalable Communication Modalities for Returning Genetic Research Results
NCT ID: NCT04407611 (https://classic.clinicaltrials.gov/show/NCT04407611)

Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)
NCT ID: NCT06006299 (https://classic.clinicaltrials.gov/show/NCT06006299)

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT ID: NCT05660083 (https://classic.clinicaltrials.gov/show/NCT05660083)

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://classic.clinicaltrials.gov/show/NCT04174352)

Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
NCT ID: NCT03833921 (https://classic.clinicaltrials.gov/show/NCT03833921)

Inspiratory Muscle Training in Obese Breast Cancer Survivors
NCT ID: NCT05193149 (https://classic.clinicaltrials.gov/show/NCT05193149)

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
NCT ID: NCT04978675 (https://classic.clinicaltrials.gov/show/NCT04978675)

REJOIN Trial for Older Breast Cancer Survivors
NCT ID: NCT03955627 (https://classic.clinicaltrials.gov/show/NCT03955627)

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT ID: NCT02064673 (https://classic.clinicaltrials.gov/show/NCT02064673)

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
NCT ID: NCT05998135 (https://classic.clinicaltrials.gov/show/NCT05998135)

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
NCT ID: NCT06269978 (https://classic.clinicaltrials.gov/show/NCT06269978)

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
NCT ID: NCT05154487 (https://classic.clinicaltrials.gov/show/NCT05154487)

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study
NCT ID: NCT06125145 (https://classic.clinicaltrials.gov/show/NCT06125145)

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
NCT ID: NCT00969111 (https://classic.clinicaltrials.gov/show/NCT00969111)

Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
NCT ID: NCT06018311 (https://classic.clinicaltrials.gov/show/NCT06018311)

Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
NCT ID: NCT06028022 (https://classic.clinicaltrials.gov/show/NCT06028022)

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma
NCT ID: NCT04903119 (https://classic.clinicaltrials.gov/show/NCT04903119)

Study of 18F-FFNP Breast PET/MRI
NCT ID: NCT06086704 (https://classic.clinicaltrials.gov/show/NCT06086704)

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation
NCT ID: NCT06258993 (https://classic.clinicaltrials.gov/show/NCT06258993)

Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
NCT ID: NCT03847311 (https://classic.clinicaltrials.gov/show/NCT03847311)

Cardiometabolic Screening Program
NCT ID: NCT05386719 (https://classic.clinicaltrials.gov/show/NCT05386719)

Understanding of Genetics by Men at Risk for Prostate Cancer
NCT ID: NCT04550845 (https://classic.clinicaltrials.gov/show/NCT04550845)

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05756166 (https://classic.clinicaltrials.gov/show/NCT05756166)

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
NCT ID: NCT03677739 (https://classic.clinicaltrials.gov/show/NCT03677739)

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NCT ID: NCT02361320 (https://classic.clinicaltrials.gov/show/NCT02361320)

Heart Health After Cancer Treatment (HEART-ACT)
NCT ID: NCT06055803 (https://classic.clinicaltrials.gov/show/NCT06055803)

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
NCT ID: NCT05961982 (https://classic.clinicaltrials.gov/show/NCT05961982)

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT ID: NCT04454528 (https://classic.clinicaltrials.gov/show/NCT04454528)

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT ID: NCT04263025 (https://classic.clinicaltrials.gov/show/NCT04263025)

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://classic.clinicaltrials.gov/show/NCT06042569)

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://classic.clinicaltrials.gov/show/NCT05376878)

A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
NCT ID: NCT03407417 (https://classic.clinicaltrials.gov/show/NCT03407417)

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
NCT ID: NCT04493333 (https://classic.clinicaltrials.gov/show/NCT04493333)

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT ID: NCT05069038 (https://classic.clinicaltrials.gov/show/NCT05069038)

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
NCT ID: NCT04995198 (https://classic.clinicaltrials.gov/show/NCT04995198)

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT ID: NCT05679674 (https://classic.clinicaltrials.gov/show/NCT05679674)

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
NCT ID: NCT04887805 (https://classic.clinicaltrials.gov/show/NCT04887805)

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT ID: NCT04203641 (https://classic.clinicaltrials.gov/show/NCT04203641)

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
NCT ID: NCT05703178 (https://classic.clinicaltrials.gov/show/NCT05703178)

Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program
NCT ID: NCT04365569 (https://classic.clinicaltrials.gov/show/NCT04365569)

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT ID: NCT05034627 (https://classic.clinicaltrials.gov/show/NCT05034627)

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://classic.clinicaltrials.gov/show/NCT04923542)

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
NCT ID: NCT04975516 (https://classic.clinicaltrials.gov/show/NCT04975516)

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://classic.clinicaltrials.gov/show/NCT04265872)

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT ID: NCT04724499 (https://classic.clinicaltrials.gov/show/NCT04724499)

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
NCT ID: NCT04870515 (https://classic.clinicaltrials.gov/show/NCT04870515)

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
NCT ID: NCT05289193 (https://classic.clinicaltrials.gov/show/NCT05289193)

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT ID: NCT04734730 (https://classic.clinicaltrials.gov/show/NCT04734730)

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
NCT ID: NCT04115163 (https://classic.clinicaltrials.gov/show/NCT04115163)

Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://classic.clinicaltrials.gov/show/NCT04998682)

Engaging Black Men in Colorectal Cancer Screening
NCT ID: NCT05980182 (https://classic.clinicaltrials.gov/show/NCT05980182)

Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT ID: NCT05700669 (https://classic.clinicaltrials.gov/show/NCT05700669)

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
NCT ID: NCT05869682 (https://classic.clinicaltrials.gov/show/NCT05869682)

Refining Local-Regional Therapy for IBC
NCT ID: NCT04636710 (https://classic.clinicaltrials.gov/show/NCT04636710)

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT ID: NCT05054296 (https://classic.clinicaltrials.gov/show/NCT05054296)

Transrectal Ultrasound Robot-Assisted Prostate Biopsy
NCT ID: NCT02871726 (https://classic.clinicaltrials.gov/show/NCT02871726)

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases
NCT ID: NCT05341349 (https://classic.clinicaltrials.gov/show/NCT05341349)

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer
NCT ID: NCT05438563 (https://classic.clinicaltrials.gov/show/NCT05438563)

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
NCT ID: NCT04116073 (https://classic.clinicaltrials.gov/show/NCT04116073)

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT ID: NCT04753879 (https://classic.clinicaltrials.gov/show/NCT04753879)

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://classic.clinicaltrials.gov/show/NCT06245889)

Internet-Based Lifestyle Intervention (iLIVE) to Eradicate Obese Frailty in Prostate Cancer Survivors
NCT ID: NCT06011499 (https://classic.clinicaltrials.gov/show/NCT06011499)

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06318273 (https://classic.clinicaltrials.gov/show/NCT06318273)

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT ID: NCT03716739 (https://classic.clinicaltrials.gov/show/NCT03716739)

Apollo Device for Metastatic Breast Cancer (MBC)
NCT ID: NCT04983342 (https://classic.clinicaltrials.gov/show/NCT04983342)

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
NCT ID: NCT05763199 (https://classic.clinicaltrials.gov/show/NCT05763199)

Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
NCT ID: NCT03987217 (https://classic.clinicaltrials.gov/show/NCT03987217)

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT ID: NCT06145399 (https://classic.clinicaltrials.gov/show/NCT06145399)

Sleep Hygiene Education, ReadiWatchTM Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia Effect, on Symptom Relief for Men With Prostate Cancer Receiving Androgen Deprivation Therapy
NCT ID: NCT05582759 (https://classic.clinicaltrials.gov/show/NCT05582759)

Impact of Protect Your Colon™ on CRC Screening
NCT ID: NCT05929820 (https://classic.clinicaltrials.gov/show/NCT05929820)

Prostate Resection After Microwave Ablation (PRAMA)
NCT ID: NCT06128525 (https://classic.clinicaltrials.gov/show/NCT06128525)

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
NCT ID: NCT03725761 (https://classic.clinicaltrials.gov/show/NCT03725761)

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT ID: NCT03856658 (https://classic.clinicaltrials.gov/show/NCT03856658)

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT ID: NCT01985828 (https://classic.clinicaltrials.gov/show/NCT01985828)

Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05447910 (https://classic.clinicaltrials.gov/show/NCT05447910)

YES Study - Newly Diagnosed/Metastatic Intervention
NCT ID: NCT04379414 (https://classic.clinicaltrials.gov/show/NCT04379414)

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT ID: NCT04668976 (https://classic.clinicaltrials.gov/show/NCT04668976)

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT ID: NCT05710328 (https://classic.clinicaltrials.gov/show/NCT05710328)

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
NCT ID: NCT05471414 (https://classic.clinicaltrials.gov/show/NCT05471414)

Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions
NCT ID: NCT02802553 (https://classic.clinicaltrials.gov/show/NCT02802553)

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://classic.clinicaltrials.gov/show/NCT02476786)

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT ID: NCT04947254 (https://classic.clinicaltrials.gov/show/NCT04947254)

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT ID: NCT03285412 (https://classic.clinicaltrials.gov/show/NCT03285412)

Breaking Through the Brain Fog: An Online Research Study
NCT ID: NCT05444231 (https://classic.clinicaltrials.gov/show/NCT05444231)

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT ID: NCT05694559 (https://classic.clinicaltrials.gov/show/NCT05694559)

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT ID: NCT04587128 (https://classic.clinicaltrials.gov/show/NCT04587128)

MRI Guided Prostate Biopsy
NCT ID: NCT06302595 (https://classic.clinicaltrials.gov/show/NCT06302595)

Metacognitive Strategy Training in Cancer-related Cognitive Impairment
NCT ID: NCT05505045 (https://classic.clinicaltrials.gov/show/NCT05505045)

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
NCT ID: NCT04722341 (https://classic.clinicaltrials.gov/show/NCT04722341)

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer
NCT ID: NCT06008158 (https://classic.clinicaltrials.gov/show/NCT06008158)

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT ID: NCT04119024 (https://classic.clinicaltrials.gov/show/NCT04119024)

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT ID: NCT04356729 (https://classic.clinicaltrials.gov/show/NCT04356729)

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT ID: NCT05036681 (https://classic.clinicaltrials.gov/show/NCT05036681)

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://classic.clinicaltrials.gov/show/NCT05464082)

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
NCT ID: NCT03772834 (https://classic.clinicaltrials.gov/show/NCT03772834)

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
NCT ID: NCT05786014 (https://classic.clinicaltrials.gov/show/NCT05786014)

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://classic.clinicaltrials.gov/show/NCT04614194)

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT ID: NCT04955743 (https://classic.clinicaltrials.gov/show/NCT04955743)

Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://classic.clinicaltrials.gov/show/NCT05219695)

An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
NCT ID: NCT06136923 (https://classic.clinicaltrials.gov/show/NCT06136923)

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
NCT ID: NCT04973930 (https://classic.clinicaltrials.gov/show/NCT04973930)

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT ID: NCT06040125 (https://classic.clinicaltrials.gov/show/NCT06040125)

Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
NCT ID: NCT04088708 (https://classic.clinicaltrials.gov/show/NCT04088708)

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://classic.clinicaltrials.gov/show/NCT04521764)

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
NCT ID: NCT04727632 (https://classic.clinicaltrials.gov/show/NCT04727632)

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer
NCT ID: NCT05996107 (https://classic.clinicaltrials.gov/show/NCT05996107)

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT ID: NCT03825289 (https://classic.clinicaltrials.gov/show/NCT03825289)

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT ID: NCT06102902 (https://classic.clinicaltrials.gov/show/NCT06102902)

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT ID: NCT06039371 (https://classic.clinicaltrials.gov/show/NCT06039371)

SMART-ER: Symptom Monitoring With Patient-reported Outcomes
NCT ID: NCT05560685 (https://classic.clinicaltrials.gov/show/NCT05560685)

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT ID: NCT03769415 (https://classic.clinicaltrials.gov/show/NCT03769415)

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT ID: NCT05155046 (https://classic.clinicaltrials.gov/show/NCT05155046)

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT ID: NCT04731844 (https://classic.clinicaltrials.gov/show/NCT04731844)

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05730712 (https://classic.clinicaltrials.gov/show/NCT05730712)

Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://classic.clinicaltrials.gov/show/NCT04563507)

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT05502315 (https://classic.clinicaltrials.gov/show/NCT05502315)

Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy
NCT ID: NCT06296147 (https://classic.clinicaltrials.gov/show/NCT06296147)

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
NCT ID: NCT06085833 (https://classic.clinicaltrials.gov/show/NCT06085833)

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
NCT ID: NCT06066437 (https://classic.clinicaltrials.gov/show/NCT06066437)

Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
NCT ID: NCT05121545 (https://classic.clinicaltrials.gov/show/NCT05121545)

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT ID: NCT05678322 (https://classic.clinicaltrials.gov/show/NCT05678322)

PET/CT Characterization of Treatment Resistance
NCT ID: NCT05647564 (https://classic.clinicaltrials.gov/show/NCT05647564)

PSMA-PET to Guide Prostatectomy
NCT ID: NCT05381103 (https://classic.clinicaltrials.gov/show/NCT05381103)

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer
NCT ID: NCT05746325 (https://classic.clinicaltrials.gov/show/NCT05746325)

Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
NCT ID: NCT05043012 (https://classic.clinicaltrials.gov/show/NCT05043012)

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
NCT ID: NCT05038332 (https://classic.clinicaltrials.gov/show/NCT05038332)

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
NCT ID: NCT05336786 (https://classic.clinicaltrials.gov/show/NCT05336786)

Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer
NCT ID: NCT04656678 (https://classic.clinicaltrials.gov/show/NCT04656678)

The Impact of Low Pressure Pneumo in RARP II
NCT ID: NCT04394676 (https://classic.clinicaltrials.gov/show/NCT04394676)

Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
NCT ID: NCT06057636 (https://classic.clinicaltrials.gov/show/NCT06057636)

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
NCT ID: NCT01984138 (https://classic.clinicaltrials.gov/show/NCT01984138)

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT04477343 (https://classic.clinicaltrials.gov/show/NCT04477343)

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT ID: NCT05765500 (https://classic.clinicaltrials.gov/show/NCT05765500)

Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT ID: NCT02290834 (https://classic.clinicaltrials.gov/show/NCT02290834)

Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT ID: NCT04233385 (https://classic.clinicaltrials.gov/show/NCT04233385)

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://classic.clinicaltrials.gov/show/NCT04648904)

Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
NCT ID: NCT02307058 (https://classic.clinicaltrials.gov/show/NCT02307058)

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT ID: NCT03995082 (https://classic.clinicaltrials.gov/show/NCT03995082)

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
NCT ID: NCT04030559 (https://classic.clinicaltrials.gov/show/NCT04030559)

Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
NCT ID: NCT05846789 (https://classic.clinicaltrials.gov/show/NCT05846789)

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://classic.clinicaltrials.gov/show/NCT04389281)

3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer
NCT ID: NCT05704283 (https://classic.clinicaltrials.gov/show/NCT05704283)

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT ID: NCT05340673 (https://classic.clinicaltrials.gov/show/NCT05340673)

Scalp Cooling in MBC
NCT ID: NCT04986579 (https://classic.clinicaltrials.gov/show/NCT04986579)

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://classic.clinicaltrials.gov/show/NCT06185205)

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT ID: NCT04120246 (https://classic.clinicaltrials.gov/show/NCT04120246)

An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
NCT ID: NCT04871139 (https://classic.clinicaltrials.gov/show/NCT04871139)

A QoL Intervention for Young African American Breast Cancer Survivors
NCT ID: NCT05452681 (https://classic.clinicaltrials.gov/show/NCT05452681)

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery
NCT ID: NCT05456373 (https://classic.clinicaltrials.gov/show/NCT05456373)

Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT ID: NCT06153836 (https://classic.clinicaltrials.gov/show/NCT06153836)

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
NCT ID: NCT05037500 (https://classic.clinicaltrials.gov/show/NCT05037500)

Efficacy of Point Of Service Testing in MBC
NCT ID: NCT03983577 (https://classic.clinicaltrials.gov/show/NCT03983577)

An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information
NCT ID: NCT06193070 (https://classic.clinicaltrials.gov/show/NCT06193070)

Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
NCT ID: NCT05591547 (https://classic.clinicaltrials.gov/show/NCT05591547)

Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://classic.clinicaltrials.gov/show/NCT04049214)

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://classic.clinicaltrials.gov/show/NCT02977468)

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT ID: NCT04030507 (https://classic.clinicaltrials.gov/show/NCT04030507)

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://classic.clinicaltrials.gov/show/NCT05990426)

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
NCT ID: NCT03880422 (https://classic.clinicaltrials.gov/show/NCT03880422)

The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors
NCT ID: NCT05983380 (https://classic.clinicaltrials.gov/show/NCT05983380)

Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors
NCT ID: NCT05674578 (https://classic.clinicaltrials.gov/show/NCT05674578)

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
NCT ID: NCT05114798 (https://classic.clinicaltrials.gov/show/NCT05114798)

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
NCT ID: NCT03844750 (https://classic.clinicaltrials.gov/show/NCT03844750)

A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer
NCT ID: NCT05243056 (https://classic.clinicaltrials.gov/show/NCT05243056)

3D Ultrasound Breast Imaging
NCT ID: NCT04692818 (https://classic.clinicaltrials.gov/show/NCT04692818)

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
NCT ID: NCT04791384 (https://classic.clinicaltrials.gov/show/NCT04791384)

Switch Maintenance in Pancreatic
NCT ID: NCT05419479 (https://classic.clinicaltrials.gov/show/NCT05419479)

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT ID: NCT03366155 (https://classic.clinicaltrials.gov/show/NCT03366155)

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
NCT ID: NCT04290897 (https://classic.clinicaltrials.gov/show/NCT04290897)

Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
NCT ID: NCT04754412 (https://classic.clinicaltrials.gov/show/NCT04754412)

Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
NCT ID: NCT05049746 (https://classic.clinicaltrials.gov/show/NCT05049746)

Personalized Self-Management Training Compared to Standardized Self-Management Training in Colorectal Cancer Patients.
NCT ID: NCT05984589 (https://classic.clinicaltrials.gov/show/NCT05984589)

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
NCT ID: NCT04717050 (https://classic.clinicaltrials.gov/show/NCT04717050)

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
NCT ID: NCT03424850 (https://classic.clinicaltrials.gov/show/NCT03424850)

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT ID: NCT04849871 (https://classic.clinicaltrials.gov/show/NCT04849871)

Re-treatment 225Ac-J591 for mCRPC
NCT ID: NCT04576871 (https://classic.clinicaltrials.gov/show/NCT04576871)

Vaginal Cuff Brachytherapy Fractionation Study
NCT ID: NCT03785288 (https://classic.clinicaltrials.gov/show/NCT03785288)

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT ID: NCT03941756 (https://classic.clinicaltrials.gov/show/NCT03941756)

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
NCT ID: NCT05388877 (https://classic.clinicaltrials.gov/show/NCT05388877)

Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT ID: NCT05298605 (https://classic.clinicaltrials.gov/show/NCT05298605)

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://classic.clinicaltrials.gov/show/NCT05095207)

Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®
NCT ID: NCT05825482 (https://classic.clinicaltrials.gov/show/NCT05825482)

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://classic.clinicaltrials.gov/show/NCT04348747)

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://classic.clinicaltrials.gov/show/NCT05677802)

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
NCT ID: NCT05689021 (https://classic.clinicaltrials.gov/show/NCT05689021)

WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT ID: NCT03824652 (https://classic.clinicaltrials.gov/show/NCT03824652)

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT ID: NCT04445844 (https://classic.clinicaltrials.gov/show/NCT04445844)

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
NCT ID: NCT05222932 (https://classic.clinicaltrials.gov/show/NCT05222932)

A Study of FRaDCs for Ovarian Cancer
NCT ID: NCT05920798 (https://classic.clinicaltrials.gov/show/NCT05920798)

Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
NCT ID: NCT05915351 (https://classic.clinicaltrials.gov/show/NCT05915351)

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
NCT ID: NCT05960578 (https://classic.clinicaltrials.gov/show/NCT05960578)

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT ID: NCT06176261 (https://classic.clinicaltrials.gov/show/NCT06176261)

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://classic.clinicaltrials.gov/show/NCT03796559)

Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings
NCT ID: NCT05785780 (https://classic.clinicaltrials.gov/show/NCT05785780)

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
NCT ID: NCT04890054 (https://classic.clinicaltrials.gov/show/NCT04890054)

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)
NCT ID: NCT05823402 (https://classic.clinicaltrials.gov/show/NCT05823402)

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
NCT ID: NCT06105918 (https://classic.clinicaltrials.gov/show/NCT06105918)

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT ID: NCT04205903 (https://classic.clinicaltrials.gov/show/NCT04205903)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://classic.clinicaltrials.gov/show/NCT04090567)

Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
NCT ID: NCT04715958 (https://classic.clinicaltrials.gov/show/NCT04715958)

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT ID: NCT03987386 (https://classic.clinicaltrials.gov/show/NCT03987386)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://classic.clinicaltrials.gov/show/NCT05319873)

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
NCT ID: NCT05752448 (https://classic.clinicaltrials.gov/show/NCT05752448)

Physical Therapy for Men Undergoing Prostatectomy
NCT ID: NCT02558946 (https://classic.clinicaltrials.gov/show/NCT02558946)

A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
NCT ID: NCT04645810 (https://classic.clinicaltrials.gov/show/NCT04645810)

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer
NCT ID: NCT06022887 (https://classic.clinicaltrials.gov/show/NCT06022887)

Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
NCT ID: NCT05975736 (https://classic.clinicaltrials.gov/show/NCT05975736)

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
NCT ID: NCT04592237 (https://classic.clinicaltrials.gov/show/NCT04592237)

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
NCT ID: NCT05226663 (https://classic.clinicaltrials.gov/show/NCT05226663)

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
NCT ID: NCT03554083 (https://classic.clinicaltrials.gov/show/NCT03554083)

Biomarkers to Detect Endocrine Therapy Resistance
NCT ID: NCT06067503 (https://classic.clinicaltrials.gov/show/NCT06067503)

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
NCT ID: NCT05692024 (https://classic.clinicaltrials.gov/show/NCT05692024)

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
NCT ID: NCT05672316 (https://classic.clinicaltrials.gov/show/NCT05672316)

Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
NCT ID: NCT03897270 (https://classic.clinicaltrials.gov/show/NCT03897270)

Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption
NCT ID: NCT06137248 (https://classic.clinicaltrials.gov/show/NCT06137248)

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT ID: NCT04013854 (https://classic.clinicaltrials.gov/show/NCT04013854)

Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)
NCT ID: NCT05716542 (https://classic.clinicaltrials.gov/show/NCT05716542)

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
NCT ID: NCT04428905 (https://classic.clinicaltrials.gov/show/NCT04428905)

Intraoperative Radiation Therapy (IORT) in DCIS
NCT ID: NCT03216421 (https://classic.clinicaltrials.gov/show/NCT03216421)

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT ID: NCT05231122 (https://classic.clinicaltrials.gov/show/NCT05231122)

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://classic.clinicaltrials.gov/show/NCT05020860)

Colonoscopy Outreach for Rural Communities Aim 2
NCT ID: NCT05453630 (https://classic.clinicaltrials.gov/show/NCT05453630)

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT ID: NCT05428007 (https://classic.clinicaltrials.gov/show/NCT05428007)

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
NCT ID: NCT05417308 (https://classic.clinicaltrials.gov/show/NCT05417308)

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
NCT ID: NCT04839614 (https://classic.clinicaltrials.gov/show/NCT04839614)

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://classic.clinicaltrials.gov/show/NCT05245812)

Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients
NCT ID: NCT04843306 (https://classic.clinicaltrials.gov/show/NCT04843306)

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT ID: NCT04789486 (https://classic.clinicaltrials.gov/show/NCT04789486)

The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
NCT ID: NCT06050395 (https://classic.clinicaltrials.gov/show/NCT06050395)

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT ID: NCT05491226 (https://classic.clinicaltrials.gov/show/NCT05491226)

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT ID: NCT04484909 (https://classic.clinicaltrials.gov/show/NCT04484909)

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://classic.clinicaltrials.gov/show/NCT06129747)

Choices About Genetic Testing And Learning Your Risk With Smart Technology
NCT ID: NCT06184867 (https://classic.clinicaltrials.gov/show/NCT06184867)

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
NCT ID: NCT04796818 (https://classic.clinicaltrials.gov/show/NCT04796818)

Using Aspirin to Improve Immunological Features of Ovarian Tumors
NCT ID: NCT05080946 (https://classic.clinicaltrials.gov/show/NCT05080946)

Bethanechol Prior to Pancreatic Surgery
NCT ID: NCT03572283 (https://classic.clinicaltrials.gov/show/NCT03572283)

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT ID: NCT05141513 (https://classic.clinicaltrials.gov/show/NCT05141513)

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT ID: NCT05256745 (https://classic.clinicaltrials.gov/show/NCT05256745)

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT ID: NCT04017650 (https://classic.clinicaltrials.gov/show/NCT04017650)

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT ID: NCT03991962 (https://classic.clinicaltrials.gov/show/NCT03991962)

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
NCT ID: NCT06237179 (https://classic.clinicaltrials.gov/show/NCT06237179)

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT ID: NCT03704662 (https://classic.clinicaltrials.gov/show/NCT03704662)

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
NCT ID: NCT05286814 (https://classic.clinicaltrials.gov/show/NCT05286814)

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
NCT ID: NCT06161506 (https://classic.clinicaltrials.gov/show/NCT06161506)

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT ID: NCT05200559 (https://classic.clinicaltrials.gov/show/NCT05200559)

MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer
NCT ID: NCT04599218 (https://classic.clinicaltrials.gov/show/NCT04599218)

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT ID: NCT04253483 (https://classic.clinicaltrials.gov/show/NCT04253483)

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT ID: NCT02451982 (https://classic.clinicaltrials.gov/show/NCT02451982)

RESIST-ADT (Androgen Deprivation Therapy)
NCT ID: NCT04485767 (https://classic.clinicaltrials.gov/show/NCT04485767)

Feasibility Study: Educational Genetic Test Video
NCT ID: NCT06166758 (https://classic.clinicaltrials.gov/show/NCT06166758)

Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://classic.clinicaltrials.gov/show/NCT05712668)

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
NCT ID: NCT03384836 (https://classic.clinicaltrials.gov/show/NCT03384836)

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT ID: NCT04683315 (https://classic.clinicaltrials.gov/show/NCT04683315)

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://classic.clinicaltrials.gov/show/NCT04677816)

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
NCT ID: NCT05634720 (https://classic.clinicaltrials.gov/show/NCT05634720)

A Culturally Sensitive Social Support Intervention
NCT ID: NCT02946697 (https://classic.clinicaltrials.gov/show/NCT02946697)

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://classic.clinicaltrials.gov/show/NCT03449238)

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
NCT ID: NCT06069778 (https://classic.clinicaltrials.gov/show/NCT06069778)

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
NCT ID: NCT05627635 (https://classic.clinicaltrials.gov/show/NCT05627635)

Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery
NCT ID: NCT05877144 (https://classic.clinicaltrials.gov/show/NCT05877144)

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
NCT ID: NCT05683964 (https://classic.clinicaltrials.gov/show/NCT05683964)

VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://classic.clinicaltrials.gov/show/NCT05608252)

Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT ID: NCT04005690 (https://classic.clinicaltrials.gov/show/NCT04005690)

11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
NCT ID: NCT04927663 (https://classic.clinicaltrials.gov/show/NCT04927663)

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT ID: NCT06112314 (https://classic.clinicaltrials.gov/show/NCT06112314)

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT ID: NCT04940286 (https://classic.clinicaltrials.gov/show/NCT04940286)

Diabetes Care for Breast Cancer Patients
NCT ID: NCT05565534 (https://classic.clinicaltrials.gov/show/NCT05565534)

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://classic.clinicaltrials.gov/show/NCT03213041)

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
NCT ID: NCT05610826 (https://classic.clinicaltrials.gov/show/NCT05610826)

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy
NCT ID: NCT06034197 (https://classic.clinicaltrials.gov/show/NCT06034197)

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
NCT ID: NCT05535192 (https://classic.clinicaltrials.gov/show/NCT05535192)

Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)
NCT ID: NCT05686122 (https://classic.clinicaltrials.gov/show/NCT05686122)

A Study of Mental Health Care in People With Cancer
NCT ID: NCT06037954 (https://classic.clinicaltrials.gov/show/NCT06037954)

A Sociolinguistic-enabled Web Application to Develop Precision Health Intervention for African Americans
NCT ID: NCT04705363 (https://classic.clinicaltrials.gov/show/NCT04705363)

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
NCT ID: NCT04915508 (https://classic.clinicaltrials.gov/show/NCT04915508)

SABR-CaRe in Early Stage Breast Cancer
NCT ID: NCT04959474 (https://classic.clinicaltrials.gov/show/NCT04959474)

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://classic.clinicaltrials.gov/show/NCT05693766)

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT ID: NCT05241249 (https://classic.clinicaltrials.gov/show/NCT05241249)

The PRIME-CRC Trial to Promote CRC Screening in Rural Communities
NCT ID: NCT04313114 (https://classic.clinicaltrials.gov/show/NCT04313114)

Educate, Assess Risk and Overcoming Barriers to Colorectal Screening Among African Americans
NCT ID: NCT03640208 (https://classic.clinicaltrials.gov/show/NCT03640208)

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://classic.clinicaltrials.gov/show/NCT05557877)

ETHAN - ET for Male BC
NCT ID: NCT05501704 (https://classic.clinicaltrials.gov/show/NCT05501704)

Improving Care After Inherited Cancer Testing
NCT ID: NCT04763915 (https://classic.clinicaltrials.gov/show/NCT04763915)

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
NCT ID: NCT04407247 (https://classic.clinicaltrials.gov/show/NCT04407247)

PHL Treatment in Pancreatic Cancer
NCT ID: NCT05365893 (https://classic.clinicaltrials.gov/show/NCT05365893)

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT ID: NCT03484299 (https://classic.clinicaltrials.gov/show/NCT03484299)

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
NCT ID: NCT05055323 (https://classic.clinicaltrials.gov/show/NCT05055323)

HIPEC After Initial CRS in Patients Who Have Received NACT
NCT ID: NCT03540017 (https://classic.clinicaltrials.gov/show/NCT03540017)

Clinical Trial of Approaches to Prostate Cancer Surgery
NCT ID: NCT05155501 (https://classic.clinicaltrials.gov/show/NCT05155501)

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT ID: NCT02452008 (https://classic.clinicaltrials.gov/show/NCT02452008)

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://classic.clinicaltrials.gov/show/NCT02830724)

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
NCT ID: NCT04981834 (https://classic.clinicaltrials.gov/show/NCT04981834)

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT ID: NCT02949284 (https://classic.clinicaltrials.gov/show/NCT02949284)

Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted Radical Prostatectomy
NCT ID: NCT04646434 (https://classic.clinicaltrials.gov/show/NCT04646434)

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT04946370 (https://classic.clinicaltrials.gov/show/NCT04946370)

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
NCT ID: NCT03073785 (https://classic.clinicaltrials.gov/show/NCT03073785)

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
NCT ID: NCT05269160 (https://classic.clinicaltrials.gov/show/NCT05269160)

A Study of Sovilnesib in Subjects With Ovarian Cancer
NCT ID: NCT06084416 (https://classic.clinicaltrials.gov/show/NCT06084416)

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT ID: NCT04599140 (https://classic.clinicaltrials.gov/show/NCT04599140)

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT ID: NCT02484404 (https://classic.clinicaltrials.gov/show/NCT02484404)

Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
NCT ID: NCT05366842 (https://classic.clinicaltrials.gov/show/NCT05366842)

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT ID: NCT03796273 (https://classic.clinicaltrials.gov/show/NCT03796273)

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT ID: NCT04305834 (https://classic.clinicaltrials.gov/show/NCT04305834)

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT ID: NCT04837209 (https://classic.clinicaltrials.gov/show/NCT04837209)

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
NCT ID: NCT05515978 (https://classic.clinicaltrials.gov/show/NCT05515978)

Exercise in Metastatic Breast Cancer: EMBody
NCT ID: NCT05468034 (https://classic.clinicaltrials.gov/show/NCT05468034)

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
NCT ID: NCT06084338 (https://classic.clinicaltrials.gov/show/NCT06084338)

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT ID: NCT06056830 (https://classic.clinicaltrials.gov/show/NCT06056830)

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
NCT ID: NCT03507608 (https://classic.clinicaltrials.gov/show/NCT03507608)

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
NCT ID: NCT04975217 (https://classic.clinicaltrials.gov/show/NCT04975217)

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT ID: NCT06234423 (https://classic.clinicaltrials.gov/show/NCT06234423)

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
NCT ID: NCT05114421 (https://classic.clinicaltrials.gov/show/NCT05114421)

Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program
NCT ID: NCT03865875 (https://classic.clinicaltrials.gov/show/NCT03865875)

Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT ID: NCT05684367 (https://classic.clinicaltrials.gov/show/NCT05684367)

The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
NCT ID: NCT06096623 (https://classic.clinicaltrials.gov/show/NCT06096623)

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
NCT ID: NCT05289830 (https://classic.clinicaltrials.gov/show/NCT05289830)

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT ID: NCT06220214 (https://classic.clinicaltrials.gov/show/NCT06220214)

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT ID: NCT04594772 (https://classic.clinicaltrials.gov/show/NCT04594772)

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT ID: NCT04606914 (https://classic.clinicaltrials.gov/show/NCT04606914)

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT ID: NCT06150664 (https://classic.clinicaltrials.gov/show/NCT06150664)

Reducing Metabolic Dysregulation in Dyads
NCT ID: NCT06117241 (https://classic.clinicaltrials.gov/show/NCT06117241)

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
NCT ID: NCT03851237 (https://classic.clinicaltrials.gov/show/NCT03851237)

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
NCT ID: NCT05458544 (https://classic.clinicaltrials.gov/show/NCT05458544)

Together After Cancer
NCT ID: NCT05645471 (https://classic.clinicaltrials.gov/show/NCT05645471)

Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial
NCT ID: NCT06016725 (https://classic.clinicaltrials.gov/show/NCT06016725)

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT ID: NCT02095184 (https://classic.clinicaltrials.gov/show/NCT02095184)

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
NCT ID: NCT04965311 (https://classic.clinicaltrials.gov/show/NCT04965311)

Methods for Increasing Genetic Testing Uptake in Michigan
NCT ID: NCT05162846 (https://classic.clinicaltrials.gov/show/NCT05162846)

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT ID: NCT06188559 (https://classic.clinicaltrials.gov/show/NCT06188559)

A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT ID: NCT05142358 (https://classic.clinicaltrials.gov/show/NCT05142358)

A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://classic.clinicaltrials.gov/show/NCT06242470)

Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT ID: NCT04444622 (https://classic.clinicaltrials.gov/show/NCT04444622)

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT ID: NCT04751435 (https://classic.clinicaltrials.gov/show/NCT04751435)

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
NCT ID: NCT04879940 (https://classic.clinicaltrials.gov/show/NCT04879940)

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
NCT ID: NCT04620603 (https://classic.clinicaltrials.gov/show/NCT04620603)

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT ID: NCT02757859 (https://classic.clinicaltrials.gov/show/NCT02757859)

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
NCT ID: NCT06112990 (https://classic.clinicaltrials.gov/show/NCT06112990)

A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer
NCT ID: NCT04990609 (https://classic.clinicaltrials.gov/show/NCT04990609)

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT ID: NCT03907527 (https://classic.clinicaltrials.gov/show/NCT03907527)

Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
NCT ID: NCT01794403 (https://classic.clinicaltrials.gov/show/NCT01794403)

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT ID: NCT04514692 (https://classic.clinicaltrials.gov/show/NCT04514692)

Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands
NCT ID: NCT06119425 (https://classic.clinicaltrials.gov/show/NCT06119425)

Cone Beam Breast CT for Breast Cancer Screening
NCT ID: NCT05036096 (https://classic.clinicaltrials.gov/show/NCT05036096)

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT ID: NCT03546686 (https://classic.clinicaltrials.gov/show/NCT03546686)

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
NCT ID: NCT05296421 (https://classic.clinicaltrials.gov/show/NCT05296421)

Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer
NCT ID: NCT05789433 (https://classic.clinicaltrials.gov/show/NCT05789433)

MR-Guided Cryoablation of Prostate Bed Recurrences
NCT ID: NCT01727284 (https://classic.clinicaltrials.gov/show/NCT01727284)

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
NCT ID: NCT03991741 (https://classic.clinicaltrials.gov/show/NCT03991741)

Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
NCT ID: NCT04443413 (https://classic.clinicaltrials.gov/show/NCT04443413)

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://classic.clinicaltrials.gov/show/NCT02422641)

GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://classic.clinicaltrials.gov/show/NCT04234386)

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://classic.clinicaltrials.gov/show/NCT05039801)

A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
NCT ID: NCT05336266 (https://classic.clinicaltrials.gov/show/NCT05336266)

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT ID: NCT05230810 (https://classic.clinicaltrials.gov/show/NCT05230810)

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT ID: NCT05455658 (https://classic.clinicaltrials.gov/show/NCT05455658)

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT ID: NCT04527900 (https://classic.clinicaltrials.gov/show/NCT04527900)

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
NCT ID: NCT04906200 (https://classic.clinicaltrials.gov/show/NCT04906200)

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT ID: NCT05954143 (https://classic.clinicaltrials.gov/show/NCT05954143)

IS-002 in Prostate Cancer
NCT ID: NCT05946603 (https://classic.clinicaltrials.gov/show/NCT05946603)

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://classic.clinicaltrials.gov/show/NCT03671044)

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04471974 (https://classic.clinicaltrials.gov/show/NCT04471974)

Social Risk Factors and Discrimination in Cancer Survivorship
NCT ID: NCT05301114 (https://classic.clinicaltrials.gov/show/NCT05301114)

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT ID: NCT04862585 (https://classic.clinicaltrials.gov/show/NCT04862585)

CanRestoreFunction Cancer-related Fatigue ( CRF )
NCT ID: NCT05868187 (https://classic.clinicaltrials.gov/show/NCT05868187)

Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients
NCT ID: NCT02891538 (https://classic.clinicaltrials.gov/show/NCT02891538)

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT ID: NCT04993313 (https://classic.clinicaltrials.gov/show/NCT04993313)

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT ID: NCT06058650 (https://classic.clinicaltrials.gov/show/NCT06058650)

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT ID: NCT02760030 (https://classic.clinicaltrials.gov/show/NCT02760030)

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://classic.clinicaltrials.gov/show/NCT04329065)

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://classic.clinicaltrials.gov/show/NCT05464810)

Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT ID: NCT03789097 (https://classic.clinicaltrials.gov/show/NCT03789097)

TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer
NCT ID: NCT05698576 (https://classic.clinicaltrials.gov/show/NCT05698576)

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)

Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain
NCT ID: NCT05412953 (https://classic.clinicaltrials.gov/show/NCT05412953)

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
NCT ID: NCT04943536 (https://classic.clinicaltrials.gov/show/NCT04943536)

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT ID: NCT05047926 (https://classic.clinicaltrials.gov/show/NCT05047926)

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
NCT ID: NCT06276491 (https://classic.clinicaltrials.gov/show/NCT06276491)

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
NCT ID: NCT05368428 (https://classic.clinicaltrials.gov/show/NCT05368428)

An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
NCT ID: NCT04837833 (https://classic.clinicaltrials.gov/show/NCT04837833)

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT ID: NCT01492972 (https://classic.clinicaltrials.gov/show/NCT01492972)

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT ID: NCT05251714 (https://classic.clinicaltrials.gov/show/NCT05251714)

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
NCT ID: NCT05677048 (https://classic.clinicaltrials.gov/show/NCT05677048)

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://classic.clinicaltrials.gov/show/NCT04899908)

Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
NCT ID: NCT05524428 (https://classic.clinicaltrials.gov/show/NCT05524428)

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer
NCT ID: NCT05271318 (https://classic.clinicaltrials.gov/show/NCT05271318)

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
NCT ID: NCT04743934 (https://classic.clinicaltrials.gov/show/NCT04743934)

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT05369000 (https://classic.clinicaltrials.gov/show/NCT05369000)

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
NCT ID: NCT05967533 (https://classic.clinicaltrials.gov/show/NCT05967533)

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
NCT ID: NCT05597878 (https://classic.clinicaltrials.gov/show/NCT05597878)

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT ID: NCT04009044 (https://classic.clinicaltrials.gov/show/NCT04009044)

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT ID: NCT06169371 (https://classic.clinicaltrials.gov/show/NCT06169371)

Mammogram Mail- and Phone-based Interventions
NCT ID: NCT05853848 (https://classic.clinicaltrials.gov/show/NCT05853848)

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT ID: NCT04946864 (https://classic.clinicaltrials.gov/show/NCT04946864)

Impact of Topical Tranexamic Acid in Breast Reconstruction
NCT ID: NCT05807074 (https://classic.clinicaltrials.gov/show/NCT05807074)

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
NCT ID: NCT05774678 (https://classic.clinicaltrials.gov/show/NCT05774678)

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT ID: NCT05754749 (https://classic.clinicaltrials.gov/show/NCT05754749)

Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT ID: NCT05744557 (https://classic.clinicaltrials.gov/show/NCT05744557)

Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
NCT ID: NCT05731791 (https://classic.clinicaltrials.gov/show/NCT05731791)

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT ID: NCT02926690 (https://classic.clinicaltrials.gov/show/NCT02926690)

IMPACT Trial: Intervention to iMProve AdherenCe Equitably
NCT ID: NCT05496829 (https://classic.clinicaltrials.gov/show/NCT05496829)

Nipple Aspirate Fluid in Detecting Breast Cancer
NCT ID: NCT03715959 (https://classic.clinicaltrials.gov/show/NCT03715959)

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://classic.clinicaltrials.gov/show/NCT05291507)

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
NCT ID: NCT05206331 (https://classic.clinicaltrials.gov/show/NCT05206331)

Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic
NCT ID: NCT05181722 (https://classic.clinicaltrials.gov/show/NCT05181722)

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04387227 (https://classic.clinicaltrials.gov/show/NCT04387227)

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
NCT ID: NCT04331041 (https://classic.clinicaltrials.gov/show/NCT04331041)

Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
NCT ID: NCT04534010 (https://classic.clinicaltrials.gov/show/NCT04534010)

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT ID: NCT03384238 (https://classic.clinicaltrials.gov/show/NCT03384238)

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
NCT ID: NCT06171607 (https://classic.clinicaltrials.gov/show/NCT06171607)

Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
NCT ID: NCT04348123 (https://classic.clinicaltrials.gov/show/NCT04348123)

Improving Genetic Counseling for BRCA+ Mothers
NCT ID: NCT04258280 (https://classic.clinicaltrials.gov/show/NCT04258280)

Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
NCT ID: NCT04225572 (https://classic.clinicaltrials.gov/show/NCT04225572)

mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients
NCT ID: NCT04175639 (https://classic.clinicaltrials.gov/show/NCT04175639)

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT ID: NCT06299163 (https://classic.clinicaltrials.gov/show/NCT06299163)

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT ID: NCT04704505 (https://classic.clinicaltrials.gov/show/NCT04704505)

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT ID: NCT03321045 (https://classic.clinicaltrials.gov/show/NCT03321045)

Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
NCT ID: NCT03238976 (https://classic.clinicaltrials.gov/show/NCT03238976)

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT ID: NCT06146920 (https://classic.clinicaltrials.gov/show/NCT06146920)

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
NCT ID: NCT02769962 (https://classic.clinicaltrials.gov/show/NCT02769962)

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT ID: NCT05637216 (https://classic.clinicaltrials.gov/show/NCT05637216)

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT ID: NCT05809752 (https://classic.clinicaltrials.gov/show/NCT05809752)

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
NCT ID: NCT03716193 (https://classic.clinicaltrials.gov/show/NCT03716193)

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
NCT ID: NCT06161493 (https://classic.clinicaltrials.gov/show/NCT06161493)

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
NCT ID: NCT03953157 (https://classic.clinicaltrials.gov/show/NCT03953157)

Ampligen Compared to No Treatment Following FOLFIRINOX in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NCT ID: NCT05494697 (https://classic.clinicaltrials.gov/show/NCT05494697)

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://classic.clinicaltrials.gov/show/NCT04771520)

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT ID: NCT06018337 (https://classic.clinicaltrials.gov/show/NCT06018337)

Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
NCT ID: NCT05056844 (https://classic.clinicaltrials.gov/show/NCT05056844)

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT ID: NCT04762979 (https://classic.clinicaltrials.gov/show/NCT04762979)

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://classic.clinicaltrials.gov/show/NCT04333706)

Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images
NCT ID: NCT05960188 (https://classic.clinicaltrials.gov/show/NCT05960188)

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT ID: NCT04282044 (https://classic.clinicaltrials.gov/show/NCT04282044)

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT ID: NCT04175431 (https://classic.clinicaltrials.gov/show/NCT04175431)

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT ID: NCT04055649 (https://classic.clinicaltrials.gov/show/NCT04055649)

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://classic.clinicaltrials.gov/show/NCT05733000)

Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://classic.clinicaltrials.gov/show/NCT06275126)

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
NCT ID: NCT04815083 (https://classic.clinicaltrials.gov/show/NCT04815083)

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction
NCT ID: NCT05316324 (https://classic.clinicaltrials.gov/show/NCT05316324)

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
NCT ID: NCT05223322 (https://classic.clinicaltrials.gov/show/NCT05223322)

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://classic.clinicaltrials.gov/show/NCT05892068)

Combination Immunotherapy in Colorectal Cancer
NCT ID: NCT05571293 (https://classic.clinicaltrials.gov/show/NCT05571293)

Walnuts and Colon Health
NCT ID: NCT05195970 (https://classic.clinicaltrials.gov/show/NCT05195970)

Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community
NCT ID: NCT05314179 (https://classic.clinicaltrials.gov/show/NCT05314179)

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT ID: NCT05655598 (https://classic.clinicaltrials.gov/show/NCT05655598)

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
NCT ID: NCT06051942 (https://classic.clinicaltrials.gov/show/NCT06051942)

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://classic.clinicaltrials.gov/show/NCT05190978)

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
NCT ID: NCT06082882 (https://classic.clinicaltrials.gov/show/NCT06082882)

Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
NCT ID: NCT05746195 (https://classic.clinicaltrials.gov/show/NCT05746195)

Real-Time Feedback (RTFB) to Improve Colonoscopy
NCT ID: NCT05241210 (https://classic.clinicaltrials.gov/show/NCT05241210)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.